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ABSTRACT 
Protein misfolding is inevitable, 30% of newly synthesized polypeptides can end up 
misfolded, and such proteins are either refolded or eliminated by cellular quality control 
pathways. These pathways include the ubiquitin proteosome system and autophagy. In recent 
years, protein misfolding has been implicated in the pathophysiology of many diseases such 
as diabetes, neurological disorders and cancer. Studies from our laboratory have shown that 
choroid plexus carcinoma tumors are characterized by the formation of aggresomes at the 
microtubules organizing centers (MTOC) in formalin fixed and paraffin embedded (FFPE) 
tumor tissues. This was further confirmed by the development of choroid plexus carcinoma 
cell line (CCHE-45) which was characterized by the constitutive formation of aggresomes at 
MTOC. Aggresome formation implies presence of toxic protein over load and/or defective 
autophagy.  The role of autophagic flux in the removal of aggresomes was further 
investigated. CCHE-45 cells displayed an increase in both basal and induced autophagic flux. 
Furthermore, microtubule-associated protein light chain 3 A- variant 1 (LC3A-V1) 
expression was silenced by promoter methylation in these cells. Restoring LC3A-V1 resulted 
in the elimination of the aggresomes and the recruitment of Lysosomal-Associated 
Membrane Protein (LAMP2) independent from autophagosome formation. Based on these 
findings we suggest that quality control autophagy in CCHE-45 is mediated by LC3A in 
aggresomes clearance. We propose that perturbation in the autophagic pathway by the 
absence of LC3A expression leads to a failure in aggresome degradation thus overcoming 
misfolded protein overload. 
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AIM OF THE STUDY 
 
Thirty percent of newly synthesized polypeptides can end up misfolded, such proteins are 
either refolded or eliminated by cellular quality control pathways which include the ubiquitin 
proteosome system and autophagy. When misfolded proteins exceed the ability of cell quality 
control to be eliminated they may end up in storage compartments. Aggresomes are 
juxtanuclear protein aggregates which act as a storage bins for misfolded proteins. In children 
Cancer hospital 57357 a new choroid plexus carcinoma cell line CCHE-45 was established. 
The cells were characterized by the presence of a single cage like inclusion body at 
juxtanuclear position that was positive for vimentin. These structures have been identified 
previously as aggresomes. The aim of the study is to characterize the mechanisms underlying 
aggresomes clearance in choroid plexus carcinoma. 
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1-LITERATURE REVIEW 
 
1.1 Tumor Biology: 
Cancer is a term that encompasses a wide class of diseases, but mainly it is used to describe 
disorders that are characterized by abnormal new growth or “neoplasm” formation. The 
ability of a neoplasm to invade the surrounding tissues or its invasive capacity is what 
governs the tendency of the tumor to be malignant and gives it the ability to further 
metastasize through blood or lymphatic vessel (Bunz, 2008). Genetic analysis on both 
chromosomal and DNA levels has revealed that neoplasms mainly originate from a single 
cell in what is known as the monoclonal origin of cancer cells (Nowell, Rowley, & Knudson, 
1998). In the late seventies, it was hypothesized that the monoclonal cancer cell has a 
selective advantage which favours its selection and allow it to proliferate and  overcome the 
neighbouring cells (Nowell, 1976). Later studies showed that cancer cells acquire genomic 
instability and accumulated changes in multiple genes which imply that more than a single 
event is required for tumorigenesis (Lengauer, Kinzler, & Vogelstein, 1998). These 
aberrations usually occur either spontaneously on a somatic level or hereditary through germ 
line mutations. Germ line cancers represent a small percentage (around 10%) of human 
cancers. Unlike somatic gene mutations, germ line cancer genes are vertically transferred in 
every cell of the carrier (Bunz, 2008). 
The accumulation of genetic and /or epigenetic aberrations lead to an acquisition of a number 
of survival mechanisms, hence enabling the tumor to grow and metastasis and most 
importantly evade apoptosis (Virani, Colacino, Kim, & Rozek, 2013). In addition to blocking 
the growth suppression mechanisms mainly involving tumor suppressor genes, inducing 
angiogenesis, indefinite proliferation, immortality and acquiring a strong capability for 
invasion and bypassing the immune system in what is known as the hallmarks of cancer 
(Hanahan & Weinberg, 2011). 
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1.2 Genetic changes contributing to cancer: 
 
On the genetic level, cancer may arise from genetic modification in either a proto-oncogene 
or a tumor suppressor gene. A proto -oncogene mutation leads to expression of a protein of a 
higher biochemical activity than its non-mutated counterpart, resulting in an alteration in 
cancer cell growth and differentiation (Camaco, 2012). Oncogenes encode proteins that play 
different roles such as transcription factors, growth factors, growth factors receptors, signal 
transduction or chromatin remodelling (Croce, 2008). The RAS gene family was among the 
first oncogenes discovered in cancer. The RAS family includes (H-ras, N-ras and K-ras) 
(Tabin & Weinberg, 1985). High mutation frequencies in these genes were reported in 
pancreatic, colorectal and lung carcinomas. Other common oncogenes includes MLL, BCL2, 
C-MYC and the ERRB families (Camaco, 2012). 
 
On the other hand, tumor suppressor genes mutation is characterized by loss of function that 
leads to perturbations in the cell cycle, genetic instability and apoptosis and ultimately results 
in disruption of homeostasis inside the cell. Mutation in the RB gene in retinoblastoma, the 
APC gene in colorectal cancer and the TP53 gene are common examples of tumor suppressor 
genes frequently mutated in cancer (Bunz, 2008). 
The most intensively studied tumor suppressor gene is the TP53 which is highly mutated in 
several human malignancies. TP53 was first discovered in 1979 by Levine and Crawford 
(Lane & Crawford, 1979; Linzer, Maltzman, & Levine, 1979). Few years later the gene was 
located on the short arm of chromosome 17 (Muleris, Salmon, Zafrani, Girodet, & Dutrillaux, 
1985). TP53 mutation could be either somatic or inherited. Germ line mutations in TP53 is 
inherited in families in what is known as Li Fraumeni syndrome (LFS) leading to 
predisposition to bone, brain especially choroid plexus carcinoma, lung and a number of soft 
tissue scarcomas (Kamihara, Rana, & Garber, 2014). Table 1 and 2 shows tumors associated 
with somatic and germ line mutations in TP53. 
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Table (1): Tumors associated with somatic mutation of TP53 according to IARC TP53 
mutation database, R17 release. TP53 mutation prevalence by tumor site, https://www.iarc.fr/ 
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Table (2): Tumors associated with TP53 germ line mutations according to IARC TP53 
mutation database, R17 release. TP53 mutation prevalence by tumor site. https://www.iarc.fr/ 
 
1.2.1:Tp53 function: 
TP53 is a transcription factor with an estimated 3,600 genes under its regulation (Li, et al., 
2012). Stressors such as DNA damage, hypoxia, pH change or starvation stimulate a number 
of TP53 upstream mediators such as ATM, ARF and ChK2. The mediators facilitate the up 
regulation of p53 through the dissociation of the P53 from its negative regulators; MDM2 an 
E3 ubiquitin ligase. The P53activation leads to either cell cycle arrest in G1 or G2 phase and 
or apoptosis (Kamihara, Rana, & Garber, 2013). 
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Figure (1): Schematic illustration of P53 pathway showing different stresses that stimulate 
TP53 upstream mediators such as ATM, ARF and ChK2. The mediators facilitate 
dissociation of P53 from its negative regulators, leading to different responses (Surget, 
Khoury & Bourdan, 2013).  
 
1.3 Epigenetic changes contributing to cancer: 
Epigenetic changes associated with cancer are changes in gene expression pattern 
independent on DNA sequence. These changes are generated by modification events in the 
DNA molecule such as post translational histone modification, DNA hypo or 
hypermethylation or changes in a micro RNA level (Sharma, Kelly, & Jones, 2010). With 
hopes of restoring normal functions of genes, epigenetic therapy is a new promising field in 
cancer treatment based on the reversibility of epigenetic mark. Currently several FDA 
approved drugs are used in cancer treatment including Temozolamide, Azacitidine and 
Decitabine (Ho, Turcan, & Chan, 2013; Sharma, et al., 2010).  
The three main epigenetic events contributing to cancer will be discussed further. 
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1 .3.1 Non coding microRNA: 
 
Micro RNAs (miRNA) are non-coding single stranded RNA molecules approximately 22 
nucleotides long (Sharma, et al., 2010). miRNA has a role in regulating posttranscriptional 
gene expression. Around 1000 micro RNA have been reported so far which down regulate 
the translation of around 60% of protein coding mRNA (Friedman, Farh, Burge, & Bartel, 
2009). In recent years, it is becoming evident that miRNA regulate many cellular process 
including development, cell proliferation and apoptosis. In addition to regulating several 
cellular processes, miRNA are have been linked several diseases including cancer (Kanwal & 
Gupta, 2012). A list of altered miRNA reported in human cancers include miR21 over 
expression in glioblastoma, prostate and lung cancer, miR-34b/34c up regulation in colon 
cancer, miR-125 up regulation in breast cancer, miR-221 and miR-222 down regulation in 
hepatocellular carcinoma and miR-92b up regulation in primary brain tumors (Kanwal & 
Gupta, 2012). Furthermore, miRNA expression profile is now used for cancer classification  
(Lu, et al., 2005). 
 
1.3.2 Histone modifications: 
In eukaryotes, the wrapping of the DNA around the histone proteins forming the nucleosome 
packs the large genome into the nucleus while still ensuring appropriate access to it for 
correct gene expression. The nucleosome core have an estimated 147 base pairs wrapped 
around a histone octamer formed of 2 copies of the highly conserved H2A, H2B, H3, H4 
histones (Henikoff & Ahmad, 2005). Histones have flexible N-terminus known as the histone 
tail, which is susceptible to a number of covalent modifications such as acetylation, 
methylation, phosphorylation and ubiquitination. Such modifications either allow formation 
of the transcriptionally inactive compact heterochromatin or the open active euchromatin. 
trimethylation of H3K4, H3K36 and H3K79 is characteristic of euchromatin, while 
methylation of H3K9, H3K27 and H4K20 is present in heterochromatin (Kanwal & Gupta, 
2012). A histone code is another epigenetic modification that regulates many DNA processes 
including repair, regulation of gene expression, replication, centromere and telomere 
maintenance. Recent research brought to light a number of mutations in genes that affect 
histones post-translational modifications such as histone deacetylases, methyltransferases, 
acetyl transferases and demethylases (Chi, Allis, & Wang, 2010). Furthermore, changes in 
histone pattern of covalent modification such as increased H3K4 dimethylation or H3K18 
acetylation have been linked to poor prognosis in cancer (Myzak & Dashwood, 2006). 
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1.3.3 CpG island and DNA methylation: 
CpG islands are short distinctively interspersed DNA sequences around 1000 base pairs (bp) 
in length. They are characterized by having a rich CG base composition; this phenomenon 
enables DNA methyltransferase to covalently attach a methyl group to 5
th
 carbon atom of 
cytosine ring situated next to a guanine nucleotide forming the CpG islands (Bunz, 2008; 
Sharma, et al., 2010). 
CpG islands are often present in transcription initiation sites and function in maintaining a 
more permissive chromatin structure which allows regulation of gene expression. In the main 
CpG island are non-methylated promoting genes to be freely expressed. Nevertheless, 
aberrant CpG island methylation has been associated with various types of cancers. This 
aberration can include different mechanisms to induce gene silencing by either inhibiting or 
activating the recruitment of regulatory proteins such as transcription factors to DNA 
(Kanwal & Gupta, 2012). 
Hypermethylated genes in cancers include tumor suppressor genes such as Rb promoter in 
retinoblastoma, MLH1 and PTEN in colorectal cancer, BRCA1 in breast cancer and ovarian 
cancer and MGMT in glioblastoma (Nagarajan & Costello, 2009; Virani, et al., 2013). Other 
genes include genes involved in DNA repair, cell cycle control and apoptosis (Sharma, et al., 
2010). 
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Table (3): Genes with hypermethylated promoter associated with cancer (How Kit, Nielsen, 
& Tost, 2012; Sharma, et al., 2010). 
 
DNA methylation pattern is used as a biomarker for early diagnosis, prognosis and following 
up patients. The methylation pattern is tested using array or sequencing based techniques. 
Some promising biomarkers include CDKN2A and RASSF1A in breast cancer, CDKN2A, 
MGMT, MLH1 in colorectal tumors, CDKN2A in lung cancer and GSTP1, RASSF1A, APC 
in prostate cancer (How Kit, Nielsen, & Tost, 2012; Sharma, et al., 2010). 
. 
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1.4 Brain tumors: 
Brain tumors are the most common pediatric solid tumor and the second most common 
childhood malignancy after leukemia representing 22% of all malignancies up to the age of 
14 and 10% of malignancies in the age group from 15 to 19 years old (Hasselblatt, et al., 
2009). The incidence rate in Egypt is 16.9 per million per year in children less than 15 years 
old (El-Gaidi, 2011). Advances in surgical intervention, chemotherapy and radiotherapy 
resulted in a humble survival improvement. Molecular characterization and deep 
investigation of underlying genetic drivers of different pediatric brain tumor are essential to 
overcome poor therapeutic outcome and dismal survival rates. 
1.4.1 Classification of primary pediatric brain tumors: 
Brain tumors were historically classified according to their anatomic location in the brain 
into: brain stem, hemispheric, diencephalic, cerebellar and optic regions tumors (Patel & Tse, 
2004). This classification system is no longer commonly used. Zulch was the first to attempt 
a histology based classification in 1979. Zulch’s classification was revised several times with 
the advancement of immunohistochemistry and genetic profiling (Patel & Tse, 2004). 
Nevertheless, the original classification based on the anatomic location of the brain tumors is 
still being used in radiological investigation. Accordingly the four main groups are: 
-Infratentorial including medulloblastoma, cerebellar astrocytomas, atypical teratoid/rhabdoid 
tumors and choroid plexus carcinoma. 
-Supratentorial tumors including low-grade cerebral hemispheric astrocytomas, high-grade or 
malignant astrocytomas, primitive neuroectodermal tumors (PNETs), ependymomas, atypical 
teratoid/rhabdoid tumors and choroid plexus carcinoma. 
-Parasellar tumors include craniopharyngiomas and germ cell tumors. 
-Spinal cord tumors include gangliogliomas, ependymomas, low-grade cerebral hemispheric 
astrocytomas and high-grade or malignant astrocytomas. 
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Figure (2): Morphological patterns of brain tumors showing the most common: astrocytoma, 
cerebellar astrocytoma, infratentorial ependymona, brain stem glioma, craniopharyngioma, 
optic glioma and medulloblastoma, www.hopkinsmedecine.org. 
 
 Currently the most commonly used classification is the World Health Organization (WHO) 
pediatric brain tumors classification which is based on the cell of origin which includes: 
- Gliomas for cells of glial origin including: astrocytomas and ependymoma. 
- Primitive neuroectodermal tumor (PNET) including medulloblastoma and supratentorial 
PNET 
- Germ cell tumors including: germinoma . 
- Other brain tumors are classified in miscellaneous group due to different cells of origin this 
group includes: craniopharyngioma, meningioma, hemangiopericytoma, hemangioblastoma  
and choroid plexus tumors (Paulino, 2011). 
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Figure (3): Classification of pediatric brain tumors according to cell of origin with 4 main 
subtypes: gliomas, PNET, germ cell tumors and miscellaneous (Paulino, 2011). 
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Table (4): Classification of pediatric brain tumors according to cell of origin (Paulino, 2011). 
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1.4.2 CBRTUS distribution statistics of pediatric brain tumors: 
The Central Brain Tumor Registry of the United States (CBTRUS) is the most 
comprehensive data bank in the united states of all the primary brain and central nervous 
system (CNS) tumors (http://www.cbtrus.org/, 2013). 
The distribution of brain tumors according to CBRTUS in children aged 0-19 show the 
highest percentage of pediatric brain tumors in the frontal, parietal, temporal, and occipital 
brain lobes representing 16.9% of childhood tumors. Figure 4 shows the distribution of 
childhood tumors by site. Unlike the adults counterparts, the most common pediatric brain 
tumor is pilocytic astrocytoma followed by medulloblastoma (Morales & Gaskill-Shipley, 
2010). 
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Figure (4): Distribution of childhood brain tumors according to CBRTUS by histology is 
shown in figure 4. (a) Represents the age group 0-14 and (b) represents the age group 14-19. 
http://www.cbtrus.org/ 
 
1.4.3 Genetic and non-genetic factors associated with childhood brain tumors: 
Exposure to ionizing radiation and presence of familial genetic syndromes correlated with the 
development of childhood brain tumors (Fleming & Chi, 2012; Paulino, 2011). Exposure to 
ionizing radiation during radiotherapy on the central nervous system (CNS) predisposes to 
secondary meningioma and malignant glioma.  Familial genetic syndromes represent around 
5% of all childhood brain tumors. Examples of familial genetic syndromes are:  
Neurofibromatosis Type 1 (NF1) which involves neurofibromin gene mutation on 
chromosome 17 resulting in mostly, optic pathway glioma.  
Neurofibromatosis Type 2 (NF2) which is presented later in life than NF1 and is caused by 
a mutation on chromosome 22 for a gene responsible for Merlin protein transcription and 
resulting in acoustic neuroma. 
Tuberous Sclerosis (TS) which is mainly associated with subependymal giant cell 
astrocytoma ependymoma and glioblastoma and was found to be linked to two genes TSC1 
on chromosome 9 and TSC2 on chromosome 16. 
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Familial Cancer Predisposition Syndromes which involves mutation on tumor suppressor 
gene (TP53) on chromosome17 and increases the risk of several solid tumors including 
astrocytoma, glioblastoma and choroid plexus carcinoma. 
Von Hippel Lindau which is caused by mutation on the VHL gene on chromosome 3 and is 
associated with Cerebellar hemangioblastoma pancreatic and kidney carcinoma. 
Other hereditary syndromes include Gorlin’s syndrome and Turcot’s syndrome. It is of great 
importance for paediatricians who care for children of familial genetic syndrome to keep a 
close follow up and to thoroughly investigate all symptoms. 
 
1.4.4 Grading of childhood brain tumors: 
 
Grading of childhood brain tumors based on the biological behavior of the neoplasm is a 
complicated procedure. It takes into consideration its proliferative power, nuclear changes, 
mitotic activity, invasiveness and necrosis (Louis, et al., 2007; Patel & Tse, 2004), based on 
which the choice of adjuvant therapy is done. The WHO sets a grading scale from (I) to (IV) 
where (I) being benign and (IV) being the most malignant. The WHO classification Grade I 
describes neoplasm of low proliferative activity and good prognosis, Grade II designates low 
proliferative infiltrative neoplasm, Grade III is for lesions which show malignant evidence 
and grade IV for malignant neoplasm with high mitotic activity (Louis, et al., 2007). 
 
1.4.5 Diagnosis and treatment: 
 
The new modalities used in brain tumors diagnosis are the computed tomography (CT) and 
magnetic resonance imaging (MRI). These modalities improved the accuracy of diagnosis 
compared to older modalities such as cerebral angiograms and pneumoencephalograms (Patel 
& Tse, 2004). The MRI using gadolinium is used in both initial diagnosis and postoperative 
assessment which is done usually 2 days post-surgical resection. MRI is able to detect the 
spread of tumor. Staging in brain tumors is not a common practice and mainly depends on 
tumor size and the location of the specimen taken, marginal specimen usually show 
invasiveness and proliferation while core specimen commonly shows necrosis. (Patel & Tse, 
2004; Paulino, 2011). 
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Treatment of brain tumor like every other solid tumor involves 3 therapeutic approaches; the 
first step is surgical resection. Even though complete resection is one of the few indicators of 
good prognosis, the surgeon still has to weigh between complete excision and trying to avoid 
any insult to the brain and possible neurological loss. The second step is usually radiotherapy. 
This step is the foundation of treatment of pediatric brain tumors. However, risks of 
developing secondary brain tumors and /or brain injury resulting in growth impairment as a 
result of exposure to ionizing radiation are still present. Lastly chemotherapy can be both 
administrated prior to resection to minimize tumor size or after excision to ensure elimination 
of cancerous cells. 
The treatment protocol is determined by a team of surgeons, oncologists and neurologists 
who take into consideration the type of the tumor, the stage and the adverse effect of the 
treatment approach. The future promises genetic and molecular targeting therapies with the 
increasing knowledge of the different molecular pathways. Ras/Raf/MAPK, 
PI3K/AKT/mTOR and sonic hedghog are three of the potential promising pathways  (Packer, 
2012). 
 
1.5 Choroid plexus: 
Choroid plexus are non-neuronal epithelial cells located in the ventricular part of the 
vertebral brain. The choroid plexus together with other cells such as the tanycytes of 
circurmventricular organs constitute the brain-CSF-Blood barrier. The main role of the 
choroid plexus is cerebrospinal fluid (CSF) production through their access to the leaky 
vessels blood compartments. CSF provides the brain and the spinal cord with many 
components that are required for normal nervous system function. In addition, it protects the 
nervous system from toxins (Wolburg & Paulus, 2010). 
Anatomically, the choroid plexus is composed of 4 parts; two of the choroid plexus are 
located in the lateral ventricles originating from the inner ventricular system forming an 
undulated leaf like structure. The third choroid plexus protrudes from the 3
rd
 ventricle 
Finally, the 4
th
 plexus is arises from caudal ventral part of the cerebellum (Strazielle & 
Ghersi-Egea, 2000). 
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1.5.1 Choroid plexus tumors: 
 
Choroid plexus tumors are rare neoplasms of the central nervous system. Although, they have 
glial origin they are classified separately from gliomas possibly due to their appearance 
which is characterized by papillary inter-ventricular growth. Fifty percent of CPT occur in the 
lateral ventricles, forty percent in the fourth ventricle and ten percent in the third ventricle or 
involve multiple ventricles (Gopal, Parker, Debski, & Parker, 2008; Wolburg & Paulus, 
2010). 
CPT accounts for 1% to 4% of all childhood brain tumors (Gopal, et al., 2008). They are 
more common in pediatric patients than in adults (Rickert & Paulus, 2001). Additionally, 
around 10% of CPT are choroid plexus carcinomas (Wolburg & Paulus, 2010). 
Choroid plexus tumors are basically classified into three major groups: choroid plexus 
papilloma (CPP) which is according to the world health organization (WHO) is a grade I 
tumor. CPP represents 80 to 90% of CPTs, they show good prognosis with gross surgical 
resection. The atypical choroid plexus papilloma (ACPP) and choroid plexus carcinoma 
(CPC) represent a smaller percentage of the CPT than CPP (Gopal, et al., 2008; Wolburg & 
Paulus, 2010). CPCs is an aggressive malignant tumor (WHO grade III) represents around 
10-20% of CPTs within the age group of 26 to 32 months old (Gopal, et al., 2008). CPCs 
have dismal prognosis which necessitate adjuvant treatment approaches. The tumor mainly 
involves the lateral and fourth ventricles (Kamaly-Asl, Shams, & Taylor, 2006). CPC is 
distinguished from CPP through their increased mitotic figures, nuclear to cytoplasm ratio 
and presence of necrosis (Hasselblatt, et al., 2006). All CPTs express vimentin, cytokeratin. 
Gene expression profiles identified more than 50 genes with different expression pattern 
found in CPC that distinguish it from CPP and ACPP (Hasselblatt, et al., 2006; Louis DN, 
2007). 
 
CPC is presented by increased intracranial pressure due to obstruction and overproduction of 
CSF. This results in many symptoms which include hydrocephalus, seizures, vomiting, 
headache, bulging fontanels and visual disturbance (Gopal, et al., 2008). 
In order to improve patients’ prognosis, complete gross resection of the tumor is necessary. 
Unfortunately, total resection is linked to higher morbidity due to the tendency of the tumor 
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to disseminate through the blood. Two thirds of the CPC tumors metastasize through the 
CSF. For the meantime, adjuvant chemotherapy and radiotherapy treatments remain 
controversial (Gopal, et al., 2008; Wolburg & Paulus, 2010). Recent studies were focused on 
using molecular targeting as treatment alternative in choroid plexus carcinoma. One study 
investigated targeting the platelet-derived growth factor receptor (PDGFR) beta using 
tyrosine kinase inhibitors. The inhibitor revealed attenuation in the proliferative activity of 
the tumor (Koos, et al., 2009). Moreover, another study conducted in the same year on the 
methylation pattern of the MGMT (O6- methylguanine-DNA methyltransferase) on choroid 
plexus carcinoma. The MGMT promoter revealed a methylation signal in 58% of the tumors 
investigated, suggesting a promising role for alkylating agents such as temozolomide in 
patients’ treatment (Hasselblatt, et al., 2009).  
 
1.5.2 Genetics of CPCs:  
Brain tumors, similar to most cancer types could develop for multiple reasons; hereditary, 
chemicals, radiation and viruses. One of the most common dysfunctions involved in CPC 
formation is related to the tumor suppressor p53, more commonly found in families with Li-
Fraumeni Syndrome (LFS) (Custodio et al., 2011). Recently, it was reported that fifty percent 
of the patients with choroid plexus carcinoma tested positive for germ-line TP53 mutations 
(Tabori et al., 2010). Furthermore, somatic mutations in TP53 have been identified in CPC 
patients (Tabori et al., 2010). Various chromosomal imbalances have been reported in studies 
of comparative genomic hybridization of CPTs. The following chromosomal additions and 
deletions have been displayed in patients with CPP: +12p; +12q, and +20p; +1, +4q, and 
+20q; +4p; +8q and +14q; +7q, +9p, and +21; -22q; -5q; -5p and -18q (Rickert et al., 2002). 
Certain imbalances were found to characterize of the type of tumor and the age of the patient 
at the time of the clinical presentation (Rickert et al., 2002).  
 
1.6 Protein folding and quality control pathways: 
 
The role of quality control pathways in protecting against misfolded and aberrant proteins has 
been under focus due to its relevance to many human cancers and neurodegenerative 
diseases. For the purpose of the work described in the thesis, protein folding and quality 
control pathways in eukaryotes will be discussed thoroughly. Protein folding is a process by 
which a polypeptide chain is converted to a functional three dimensional protein molecule 
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(Roman & Gonzalez Flecha, 2014). The process requires the assistance of multiple 
chaperons. As any other machinery folding may encounter several obstacles. These problems 
result in misfolded proteins (Garcia-Mata, Gao, & Sztul, 2002). Thirty percent of newly 
nascent polypeptide ends up being misfolded. Misfolding may be a result of errors in 
transcription, translation or due to environmental factors causing thermal, oxidative or 
osmotic stress. Such misfolded proteins may be refolded or eliminated using quality control 
mechanisms (Garcia-Mata, et al., 2002; Yao, 2010). 
 
1.7 Quality control pathways: 
 
Cell maintains the proteome homeostasis through balancing de novo protein synthesis and 
aberrant or misfolded protein degradation. The process of protein transcription and translation 
are extensively covered through many studies. On the other hand, protein degradation has not 
received the same attention until the beginning of the year 1940 (Lilienbaum, 2013). The 
process of protein degradation is governed by three major different yet interconnected 
pathways (Lilienbaum, 2013; Yao, 2010): 
- First, the molecular chaperone pathway uses heat shock proteins (HSPs) to help 
efficient refolding of misfolded proteins. 
- Second, the Ubiquitin Proteasome System (UPS) which is responsible for eradication 
of the majority of damaged, denatured and misfolded proteins. 
-Third, the autophagy system which is an alternative pathway for elimination of 
abnormal protein aggregates. 
The UPS and the autophagy pathways play a key role in energy production during starvation 
in addition to their role as quality control machinery. 
 
1.7.1 The ubiquitin proteasome pathway: 
The process of intracellular misfolded protein elimination is initiated by covalent attachment 
of one ubiquitin (Ub) molecule to a lysine residue on the protein to be degraded (Lilienbaum, 
2013). Ubiquitin protein is a conserve 76 amino acid polypeptide which possess 7 lysine 
residues for subsequent ubiquitin bonding in a process known as poly ubiquitination 
(Hershko & Ciechanover, 1998) The process is activated by the successive activity of three 
enzymes : ubiquitin activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin 
ligase (E3). The action is done through energy release from ATP (Lilienbaum, 2013). 
Depending on the length and positioning of ubiquitin moieties, different cell machinery are 
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recruited for degradation. The most abundant form is lysine 48 Ub which act as a signal for 
26S proteasome degradation (Kravtsova-Ivantsiv & Ciechanover, 2012). The barrel shaped 
26S proteasome has a channel structure through which the polyubiquinated misfolded protein 
gets degraded by specific enzymes (Groll & Huber, 2003). On the other hand, lysine 63 Ub 
has been recently associated with being a signal for non-proteasomal pathway including 
identification by aggresomes and autophagy pathway (Lilienbaum, 2013). 
 
 
Figure (5): Schematic illustration of the ubiquitin proteasome pathway. The process is 
activated by the successive activity of 3 enzymes E1, E2 and E3; the barrel shaped 26S 
proteasome has a channel structure through which the polyubiquinated misfolded protein gets 
degraded by specific enzymes (Kinayamu, Chen, & Archur, 2005). 
 
1.7.2 Autophagy: 
 
Autophagy is a dynamic catabolic multistep process for elimination of toxic and misfolded 
proteins. The process is essential for cell protection against many diseases including cancers, 
infectious diseases, neurodegenerative and myodegenerative diseases (Loos, Engelbrecht, 
Lockshin, Klionsky, & Zakeri, 2013). 
Autophagy is a Greek term which means “self -eating”. The cell recycles cytosolic 
components to be able to survive in stress conditions. There are three main types of 
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autophagy: macroautophagy, microautophagy, and chaperone mediated autophagy (CMA). 
Each type of autophagy has a different function and pathway. The most characteristic is 
macroautophagy which will be referred to as autophagy in the remaining part of the literature 
(Chen & Klionsky, 2011).  
 
 
 
1.7.3 Macroautophagy pathway: 
 
Autophagy is an essential catabolic process necessary to homeostasis inside the cell. It is 
mainly upregulated in cases of nutrient starvation, oncogene activation, infections and 
hypoxia (Rosenfeldt & Ryan, 2011). The process starts by formation of a crescent shaped 
sequestering double membrane compartment containing cell materials to be degraded, known 
as phagophore. The phagophore then elongates into autophagosome which subsequently 
fuses with the lysosome forming an autolysosome structure for subsequent degradation 
(Klionsky, et al., 2008). 
 
 
 
Figure (6): Schematic illustration of the macroautophagy pathway. The process starts by 
phagophore formation followed by elongation into autophagosome. The autophagosome then 
fuses with the lysosome releasing hydrolases for protein degradation (Grasso, Ropolo, & 
Vaccaro, 2015). 
 
The machinery of autophagy is operated by a number of compounds which facilitate the 
fusion of the autophagosome with the lysosomes forming the autolysosmes, where toxic 
proteins are degraded. The process is initiated by the nucleation of the phagophore with the 
help of the autophagy effector activity of LC3; the phagophore is then assembled in a 
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phagophore assembly site (PAS). This assembly is done under the control of class III 
phosphatidylinositol 3-kinases (PI3K) (Lilienbaum, 2013; Mizushima, Yoshimori, & 
Ohsumi, 2011). The phagophore is later expanded in an elongation step forming the mature 
autophagosome. Two ubiquitin like (Ubl) complexes involved in the process; the Atg12-Atg5 
ubiquitin-like conjugation system and the Atg8 proteins (Johansen & Lamark, 2011). The 
mammalian ortholog of Atg8 are the LC3 variants: LC3A, LC3B, LC3C, GABARAP (γ-
AminoButyrate acid receptor-associated protein), GABARAPL1 (GABARAP-Like protein) 
(Lilienbaum, 2013). At this step LC3-I is cleaved then lipidated to the LC3-II isoform, which 
is then, incorporated into the autophagosome. The LC3-II is one of the specific markers for 
autophagy (Chen & Klionsky, 2011). The autophagosome then fuses with lysosome forming 
autolysosome in the maturation step for subsequent degradation by specific hydrolases, The 
autophagic process is highly regulated machinery and its miss-regulation is linked to many 
diseases including cancers (Lilienbaum, 2013). 
 
1.7.4 Diseases associated with impaired autophagy: 
 
 Genetic connection between autophagy and cancer has been reported in several studies. 
Tumor suppressor genes were found to activate autophagy. On the other hand, oncogenes 
were linked to autophagy inhibition (Todde, Veenhuis, & van der Klei, 2009). In addition to 
their ambiguous role in cancers, perturbed autophagy was found to contribute to various 
diseases including neurodegenerative, cardiovascular and inflammatory diseases. Many 
autophagy genes were found inactivated in human cancers (Klionsky, et al., 2008; Rosenfeldt 
& Ryan, 2011; Sarkar, et al., 2013). 
The autopahgy related gene, ATG Beclin1 hemizygosity was detected in a high percentage in 
human breast, ovarian and prostate cancers. Alternatively, the ectopic gene transfer was 
found to inhibit tumor growth in mouse and human xenograft models (Levine & Kroemer, 
2008; Rosenfeldt & Ryan, 2011; Todde, et al., 2009). UV radiation resistance-associated 
gene protein  (UVRAG ), ATG5 and ATG12  mutations were reported in colon and gastric 
cancer .The p62/SQSTM1 was found overly  expressed in breast and lung cancer (Schmukler, 
Kloog, & Pinkas-Kramarski, 2014). 
 
1.7.5 The role of LC3 in autophagy:  
The microtubule-associated protein light chain 3 (LC3) is the mammalian homologue of yeast 
ATG8 that was first detected to localize to autophagosome in the year 2000 by Kabeya et al 
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using electron microscopy (Kabeya, et al., 2000). LC3 and LC3 tagged with GFP are the 
markers of choice to monitor the autophagic process either by Western blot, 
immunofluorescence or life imaging (Klionsky, et al., 2008). 
The process of LC3 lipidation begins with the endopeptidaseATG4 which cleaves the LC3 
exposing Carboxyl terminal glycine forming the LC3I. An E1-like enzyme (ATG 7) then 
activates the LC3I.  Next, with the help of a second E2-like enzyme (ATG3) the conjugation 
of phosphatidylethanolamine (PE) moiety is catalyzed forming the lapidated LC3II (lc3-PE) 
(Chen & Klionsky, 2011; Tanida, Ueno, & Kominami, 2004). 
 
1.7.6 LC3 gene and methylation: 
The process of autophagy requires LC3 in the process of nucleation and elongation of 
phagophore. A recent study in 2012 (Bai, Inoue, Kawano, & Inazawa, 2012) classified  
human LC3 gene family into five members: LC3A variant1:V1, LC3A variant 2, LC3B, 
LC3B2 and LC3C. 
LC3A-V1 and V2 differ in their transcriptional start site and their N-terminal amino acid 
sequence. On the other hand LC3B1 and LC3B2 has different locus and differ in only 1 
amino acid. LC3B was always considered as the key player in autophagy. In the former 
study, they were able to prove that LC3B and LC3A-V1 play a major role in autophagy. 
Another interesting finding was the LC3A-V1 may have a tumor suppressive activity. 
Therefore, its inhibition may lead to carcinogenesis. Perturbations in autophagy genes on the 
genetic and epigenetic level were found to trigger cancer development. Epigenetic LC3A- V1 
inactivation by DNA methylation was detected in many cancer cell lines. Restoration of 
LC3A-V1 protein by stable re-expression was found to inhibit tumor growth in vivo in 
oesophageal squamous cell carcinoma (ESCC) cell lines (Bai, Inoue, Kawano, & Inazawa, 
2012). 
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Figure (7): Human LC3 genes exon-intron structure, the diagram shows two variants for 
LC3A gene with 2 different  transcriptional start sites (Bai, Inoue, Kawano, & Inazawa, 
2012). 
 
 Cell lines with LC3Av1 silencing: 45.5% of all cell lines had LC3Av1 silenced while they 
all showed LC3B expression. 
 
 
Table (5): Different cancer cell lines and the percentage of LC3Av1 silencing (Bai, Inoue, 
Kawano, & Inazawa, 2012). 
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1.8 Aggresome and autophagy: 
 
Aggresomes are juxtanuclear protein aggregates which act as storage bins for misfolded 
proteins. They are localized in the microtubule organizing center (MTOC). Proteins 
sequestered in aggresomes are mainly cleared by autopagy (Yao, 2010). 
The aggresomes were first identified by kopito lab in the year 2000. However, their exact 
composition is still not completely identified. Ubiquitin, Hsps 27, 70 and 90 and HDAC6 are 
key components in the aggresome structure (Richter-Landsberg & Leyk, 2013; Yao, 2010). 
 
 
 
1.8 .1 Aggresome pathway: 
When nascent polypeptide gets misfolded either due to failure in refolding or a dysfunction in 
the proteasome pathway, they aggregate to form aggresomal particles. These particles travel 
quickly towards the (MTOC) where they form the aggresome (1-3um) (Garcia-Mata, et al., 
2002). This active process requires dynein/dynactin motor complex transport function and 
histone deactylase 6 (HDAC6) associations (Garcia-Mata, Bebok, Sorscher, & Sztul, 1999; 
Yao, 2010). The process is accompanied by reorganization of intermediate filament (IF) 
cytoskeleton protein vimentin forming a  peri-centeriolar cage around the aggresome (Garcia-
Mata, et al., 2002). Accumulation of toxic proteins in aggresome facilitates their degradation 
through autophagy (Lee, Shin, Choi, Lee, & Lee, 2002). This rescue machinery protects the 
cell from undesirable misfolded proteins and help in cell survival. 
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Figure (8): The aggresome pathway: misfolded proteins that don’t get eliminated by the 
proteasomal system are transported by the help of HDAC6 and dynein motor to the MTOC 
region to be eliminated by autophagy (Rodriguez-Gonzalez, Lin, keda, Simms-Waldrip, et 
al., 2008). 
 
Abnormal accumulation of poly-ubiquitinated misfolded protein aggregates has been reported 
in a number of neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s 
disease (PD), Huntington’s disease (HD), Lewybody dementia and amyotrophic lateral 
sclerosis (ALS) (Takalo, Salminen, Soininen, Hiltunen, & Haapasalo, 2013). 
In Alzheimer’s disease (AD) 2 different types of aggregates are reported: β amyloid peptide 
plaques found extracellular and the intracellular hyperphosphorylated tau proteins (Glenner & 
Wong, 1984; Kosik, Joachim, & Selkoe, 1986). In Parkinson disease (PD), accumulation of 
intracellular aggregates of synuclein in Lewy bodies is a common feature (Spillantini, et al., 
1997). In Huntington’s disease (HD) aggregates of polyglutamine (Poly-Q) extension 
containing Huntington protein are characteristic for the disease (DiFiglia, et al., 1997). Super 
oxide dismutase (SOD) aggregates in amyotrophic lateral sclerosis (ALS) are found in motor 
neurons (Bruijn, et al., 1998). 
Inclusion body formation is a healthy mechanism for cell protection, however when their 
accumulation exceeds ability of quality control pathways to degrade the misfolded proteins 
they may target different compartments depending on their ubiquitination status and 
solubility. In Addition to the aggresome as compartment for insoluble ubiquitinated proteins, 
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they transport the misfolded protein for clearance by autophagy at the MTOC. Two different 
types of compartments where reported as targets for aggregated proteins: 
-The Juxtanuclear quality control (JUNQ) which is a destination for soluble ubiquinated 
misfolded proteins. The aggregated proteins are either refolded or degraded using 
proteasome. The JUNQ is located in close proximity to the nucleus (Kaganovich, Kopito, & 
Frydman, 2008). 
The insoluble protein deposit (IPOD) is non-membrane bound. The IPOD recruits the 
autophagy machinery for the disposal of insoluble non ubiquitinated aggregates such as in 
Huntington disease polyQ Huntington protein and prions (Kaganovich, et al., 2008). 
Compartmentalization of inclusion bodies and misfolded protein decrease their toxicity, 
improve their refolding through chaperon aid and boost the clearance process by proteasome 
or autophagy preventing their cross reaction with other active proteins. 
 
1.9 Cross talk between UPS  and autophagy 
 
The aggresome/autophagy and the UPS pathways were long thought to be independent. 
Recent studies have shown several areas of crosstalk and complementation between both 
pathways in order to maintain homeostasis inside the cell. First level of interaction depends 
on the nature of protein to be degraded. Most short lived proteins favor degradation through 
the UPS system. Alternatively, long lived proteins and in case of proteasome overloading, 
misfolded proteins tend to form aggresomes as substrate for autophagy (Lilienbaum, 2013). 
Second level of cross talk identifies the ubiquitin tagging of the protein. The K48Ub tag 
favors degradation by 26S proteasome (Kravtsova-Ivantsiv & Ciechanover, 2012), while 
K63Ub is a substrate for aggresome autophagy pathway (Tan, et al., 2008). 
Third level of interfacing is the adaptor molecules which get attached to ubiquitnated proteins 
such as p62/sequestome-1 (SQSTM1) and BRCA1 (NBR) both of which have higher affinity 
to the K63 chains thus, they help in recruiting autophagic and not the proteasomal machinery 
(Kirkin, Lamark, Johansen, & Dikic, 2009). Another key molecule is HDAC6 which has a 
ubiquitin binding domain at its C- terminal and plays a role in aggresomes formation and 
transferring both the autophagosomes and lysosomes to the MTOC. Perturbation in UPS was 
found to redirect ubiquitinated protein aggregates into aggresome formation and hence 
elimination by autophagy (Driscoll & Chowdhury, 2012). Synergetic inhibition of both 
proteasomal and autophagy pathways is currently under investigation as powerful anticancer 
therapy. 
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1.10 HDAC6 and inhibitors: 
Histone deacetylases (HDACs) are a group of enzymes that deactylate histones lysine 
residues as opposed to the action of histone acetyl transferases (HATs). Histones acetylation 
and deactylation play a role in chromatin dynamics and regulation of gene expression 
(Simoes-Pires, et al., 2013). However, more than 50 non histone substrates have been 
identified as HDACs targets (Fischer, Sananbenesi, Mungenast, & Tsai, 2010). HDACs are 
classified into four main classes based on yeast HDAC homology. Class I, II and IV activity 
includes Zn dependent mechanism, while class II is a NAD+ dependent mechanism. Class I 
has four isoforms (HDAC1, 2, 3 and 8), class III has 7 isoforms while class I has only 
HDAC11 isoform. Class II has 2 subclasses and 6 isoforms from which HDAC6 is in class 
IIb (Yang, Zhang, Zhang, Zhang, & Xu, 2013). The class HDAC6 plays a major role in the 
process of elimination of aggresomes (Simoes-Pires, et al., 2013). 
HDAC6 is a 1215 amino acid protein structure with 2 catalytic deactylase domains (DD1 and 
DD2), the catalytic deactylase domain DD2 was found to play a major role in tubulin 
deactylation (Finnin, et al., 1999; Yang, et al., 2013). In addition, a zinc finger UBD was 
found at the C-terminal to bind with high affinity to ubiquitinated proteins. A dynein binding 
domain (DBM) is also present to facilitate the transport of ubiquitinated proteins along the 
microtubules towards the MTOC. HDAC6 recruits an actin remodelling system which helps 
in F-actin network assembly. This network assembly controls autophagosome and lysosome 
assembly (HDAC6-P62). Recent studies showed that HDAC6-deficient cells are unable to 
form large aggresome hence, misfolded protein elimination is impaired (Richter-Landsberg & 
Leyk, 2013). 
 
HDACs inhibitors have been considered as novel potent cancer therapies. Unlike HDAC 
inhibitors, tubacin doesn’t affect whole histone acetylation or gene expression (Richter-
Landsberg & Leyk, 2013). Instead, it increases α-tubulin acetylation and inhibits aggresome 
formation through its interference with HDAC6 /dynein interaction. 
 
1.11 mTOR pathway, an overview: 
The mammalian target of rapamycin (mTOR) is a highly conserved 289 kD a serine–
threonine kinase. It plays a role in regulation of cell growth, proliferation, metabolism and 
survival (Abraham, 2001). The mTOR belongs to the phosphatidylinositol kinase-related 
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protein kinases family, and its activation was reported in many human cancers. Two distinct 
mTOR complexes exist. The mTOR complex1 (mTORC1) composed of mTOR, raptor, 
PRAS40 and mLST8/GbL. The mTORC1 plays a role in protein synthesis and cell cycle, 
angiogenesis and autophagy. This complex exhibits sensitivity to rapamycin (Kim & 
Sabatini, 2004; Zaytseva, Valentino, Gulhati, & Evers, 2012). Second, The mTOR complex 2 
(mTORC2) is composed of mTOR, rictor, mSIN1, mLST8/GbL, protor-1 and PRR5. The 
mTORC2 function includes cell survival, proliferation and actin cytoskeleton organization. 
Phosphatidylinositol3-kinase (PI3K)/Akt pathway/mTOR pathway was found to be 
deregulated in various types of cancers (Laplante & Sabatini, 2009; Zaytseva, et al., 2012). 
Targeting this pathway is an attractive goal for anticancer therapy. 
Growth factors are the main activators of mTOR pathway. Among these growth factors are 
epidermal growth factor, and insulin like growth factor. They bind to their respective 
receptors such as receptor tyrosine kinase (RTK) eventually, this activates downstream 
signals such as PI3K (Engelman, Luo, & Cantley, 2006).   
PI3K phosphorylates lipid phosphatidyl inositol 4-5 bisphosphate (PIP2) to the active 
phosphatidyl inositol 3, 4, 5, trisphosphate (PIP3) (Frech, et al., 1997). In turn, PIP3 recruits 
PH containing domain AKT phosphoinositide-dependent kinase to the cell membrane in 
parallel to recruiting 3-phosphoinositidedependent protein kinase 1 (PDK1) which 
phosphorylates AKT at threonine 308 (Thr 308) residue (Yap, et al., 2008). Further 
phosphorylation of AKT C-terminal serine 473 (ser473) by mTORC2 is mandatory for full 
AKT activation (Hennessy, Smith, Ram, Lu, & Mills, 2005). mTORC1 phosphorylates 
downstream p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein 1 
(4E-BP1). Both targets play a role in translation initiation. In addition, p70s6 Kinase has a 
feedback role in PI3K/AKT pathway inhibition (Zaytseva, et al., 2012). 
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Figure (9): The mTOR pathway showing the activating nodes, AKT, PDK1, PI3K  mTORC1 
and mTORC2 and the negative feedback regulators PTEN and TSC complex (Dienstman, 
Rodon, Serra, & Tabernero, 2014). 
Rapamycin and its analogs target mTOR inhibition through forming a complex with FKBP-
12 which inhibits mTORC1 but not mTORC2 (Liu, Thoreen, Wang, Sabatini, & Gray, 2009). 
The drawback with rapamycin and its analogues that the S6K-mediated negative feedback 
loop is blocked by mtorc1 inhibition, leading to hyperactivation of PI3K signalling which in 
turn increases the phosphorylation of Akt -Ser473 and upregulates mTORC2 leading to 
further activation of AKT (Efeyan & Sabatini, 2010). 
This limitation of rapamycin and its analogues lead to emergence of second generation 
mTORC1-mTORC2 dual inhibitors also known as ATP-competitive mTOR kinase inhibitors 
such as pp242, AZD, torin 1 and 2. Those inhibitors are able to block PI3K/Akt feedback 
signalling (Zaytseva, et al., 2012). In autophagy, the initial sequestration process is regulated 
by autophagy-related gene (Atg) products and mTOR proteins. mTOR pathway is activated 
by nutrients and growth factors which interacts with the cell membrane, starvation and lack 
of sufficient nutrients lead to mTOR  inhibition and further activation of autophagy 
(Strimpakos, Karapanagiotou, Saif, & Syrigos, 2009). 
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Nutrients which enter the cell by passive diffusion activate mTORC1 through either direct 
interaction with mTORC1 or inhibition of tuberous sclerosis complex 1/2 (TSC1/2). 
Furthermore, low adenosine 5-triphosphate (ATP) production caused by energy deprivation 
causes activation of AMP dependent kinase (AMPK) deriving TSC1/2 activation hence, 
mTORC1 inhibition (Gao, et al., 2002). 
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2-MATERIALS AND METHODS 
 
2.1-Specimen Collection: 
 
Tumors diagnosis was carried out at the Department of Pathology, Children's Cancer Hospital 
Egypt 57357. Patients under 18 years of age diagnosed with choroid plexus carcinoma, 
papilloma or atypical choroid plexus papilloma with no prior exposure to radiotherapy or 
chemotherapy treatment were enrolled in the study. The study protocol was approved by the 
Children's Cancer Hospital Institutional Review Board (IRB). Informed consent was obtained 
from the patients or care-givers for the analysis of the stored samples (tissue) in this proposed 
study. Standard histological H&E preparations of the tumors were used to establish diagnosis 
for choroid plexus carcinoma and papilloma according to the WHO histological criteria. 
  
2.2- Establishment of CCHE-45 Cell Line: 
 
For the generation of the choroid plexus carcinoma cell line, half of the biopsy was paraffin 
embedded for histopathology and a small piece was further processed for culturing. For the 
generation of CCHE-45 cell line, tumor biopsy was initially minced and then cultured in 
RPMI media supplemented with 10% fetal bovine serum (FBS) and 5% antibiotics mixture of 
Streptomycin-penicillin-Amphotercin B (Lonza, Maryland, USA) at 37 
0
C and 5% CO2. Cells 
were regarded as immortal and stable after 40 passages, the cell line was established by Dr 
Shahenda El-Naggar lab team. CCHE-45 cell line was authenticated using Multiplex Cell 
Authentication by Multiplexion (Heidelberg, Germany). The SNP profiles for the cells and 
the tumor matched and were unique. 
 
2.3- Karyotype and FISH Analysis: 
 
Metaphase preparations were obtained from cell lines according to standard cytogenetics 
procedures. Giemsa staining and clonal chromosomal abnormalities were described according 
to the International System for Human Cytogenetic Nomenclature. FISH was performed on 
metaphase preparations from the same culture passage as conventional karyotyping. Whole 
chromosome paint and TP53/D17Z1 probes were used according to the manufacturer's 
instructions (Metasystems, Germany and Abbott, USA). The slides were analysed using 
Lieca DM5500 B microscope; subsequently image acquisition using JAI video camera and 
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image analyzer system (Applied Imaging Ltd) were used. The former experiments were 
conducted by cytogenetics team at Children Cancer Hospital Egypt 57357 under the 
supervision of Dr. Sherine Saleem. 
 
2.4- Cell lines, Induction of Autophagy and Drug Treatment: 
 
Neuroblastoma SH-SY5Y and SKNAS cell lines are a kind gift from Dr. Juma Mora at Sant 
Joan De Deu, Barcelona. Cells were authenticated using AmpFlSTR® SGM Plus® PCR 
Amplification Kit. Cells were grown in RPMI media containing 10% FBS and 1% antibiotics 
mixture of Streptomycin-penicillin-Amphotercin B (Lonza, Maryland, USA) at 37 
0
C and 5% 
CO2. For induction of autophagy cells were serum starved in Hank's balanced salt solution 
(HBSS, Lonza, Maryland, USA) for 2 and 6 hours. For HDAC6 inhibition cells were treated 
with 15 μM tubacin or nil-tubacin (Enzo Life Sciences, New York, USA). For 5-AZA-dC 
treatment, cells were treated with either DMSO or 10 mM for 4 successive days (Sigma 
Aldrich, St Louis, Missouri, USA). 
 
2.5- Western Blot Analysis: 
 
Whole-cell lysates from both CCHE-45 and SH-SY5Y cell lines were prepared using RIPA 
lysis buffer (G-Biosciences, Missouri, USA) supplemented with protease and phosphatase 
inhibitors (ThermoScientific, Rockford, Illinois, USA). For Soluble and insoluble fraction 
protein isolation, cells were collected from 35 mm dishes and were lysed on ice for 30 min 
using 0.1% Triton X- PBS plus protease inhibitors (ThermoScientific, Rockford, Illinois, 
USA). Total cell extracts were centrifuged submitted 30 minute at 16,000 g to separate 
soluble (supernatant) and insoluble (pellet) fractions. The insoluble fraction was then 
resuspended in 1% SDS solution in 1X PBS. The proteins concentration was determined 
using Coomassie protein assay (Thermoscientific, Rockford, Illinois, USA). Protein lysate 
was resolved by SDS–PAGE (Bio-Rad, Berkely, California, USA) and blotted onto a PVDF 
membrane. After blocking with 5% non-fat dry milk in TBST for 1 hour, the membrane was 
incubated with primary antibody overnight at 4 
0
C. 
 The following primary antibodies were used with (1:1000) dilutions: rabbit anti-LC3A, 
rabbit anti-LC3B, mouse HDAC1, mouse ubiquitin, mouse anti-vimentin , mouse anti β-
Actin (Cell Signalling Technology, Danvers, Massachusetts, USA) and mouse anti-acetylated 
alpha tubulin (Santa-Cruz Biotechnology, Santa Cruz, California, USA). The membrane was 
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washed 3 times with TBS each for 15 mins followed by secondary anti-mouse (1/5000) or 
anti-rabbit (1/5000) antibody for 1 hour. The membrane was then washed with TBS 3 times 
for 15 minutes each. Bounded antibodies were visualized using ECL chemiluminescence 
Western blot substrate (ThermoScientific Rockford, Illinois, USA). 
 
2.6- Immunostaining and Immunofluorescence: 
 
Automated immunostaining was carried out using Ventana BenchMarkXT platform using 
vimentin (Ventana,Tucson, Arizona, USA). The following antibodies were then used; 
vimentin, cytokeratin (Abcam, Cambridge, Massachusetts, USA), LC3A (Abgent, San Diego, 
California, USA) and LC3B. For immunofluorescence, cells were then fixed with 4% 
paraformaldehyde, washed with PBS, permeabilised and blocked in 5% normal goat serum 
and 0.2% Tween 20 at room temperature for 1h. Cells were then incubated at 37
0
C with 
primary antibody overnight in humidified chamber, the following primary antibodies were 
used at the following concentrations rabbit anti-LC3A (1:50), rabbit anti-LC3B (1:50), mouse 
anti-vimentin (1:25), rabbit anti-HDAC6 (1:50) and mouse anti-acetylated α-tubulin (1:25). 
Cells were then washed with PBS and bound antibodies were visualized using the following 
secondary antibodies; Alexa Fluor 555 goat anti-mouse or Alexa Fluor 488 goat anti-rabbit 
antibody (1:500) (Cell Signaling Danvers, Massachusetts, USA) at room temperature for 
1hour. After three further washes in PBS, cells were then counterstained using 4′, 6-
diamidinophenylindole (DAPI). Images were acquired using LSM 710 confocal scanning 
laser microscope (Carl Zeiss, Thornwood, New York, USA). 
 
2.7- Electron Microscopy:  
 
Cell processing and EM imaging was performed at TEM Cairo University Research Park. In 
brief, cells were collected from plates using PBS then fixed with osmium tetroxide and 
glutaraldehyde, then dehydrated in different concentrations of alcohol and embedded in the 
selected epoxy resin. Microtome sections were then prepared at approximately 500 to 1000 
µm of thickness with a Leica Ultracut ultramicrotome UCT (Leica Microsystems, Germany). 
Thin sections were stained with tolodin blue (1X). Ultrathin sections were prepared at 
approximately 75 to 90 of µm thickness and stained with lead citrate and uranyl acetate. 
Sections were examined using JEOL (JEM-1400 TEM) and captured by CCD camera AMT, 
optronics camera with 1632 x 1632 pixel format as side mount configuration. 
47 
 
 
2.8- Proteasome Activity Assay: 
 
Three cell lines (CCHE-45, SH-SY5Y, SKNAS) were cultured overnight in a black wall 
transparent bottom 96 well plate.  Cells were cultured at 500,000 cells/100ul/well at 37
O
C 
and 5%CO2. The next day 100 µl of proteosome assay loading solution (Abcam, Cambridge, 
Massachusetts, USA) were applied and incubated at 37
 O
C for 4 hours and read at EX/EM 
490/620 nm. 
 
2.9- Cell Viability Assay: 
 
Cells were platted at density 3000 cells/ well on a 96 well plate for 24 hours prior to 
treatment. Cells were treated with, tubacin, niltubacin (Life Sciences, New York, USA) or 
DMSO. After 48 hours the cells were then treated WST-1 (Clonetech, Mountain View, 
California, USA) which measures cell proliferation for 4 hours. Absorbance was measured at 
440 nm using a spectrophotometric microplate reader (Sunrise, Tecan, Männedorf, 
Switzerland). All experiments were performed at least three times. Error bars represent ± 
SEM. The absorbance values were normalized to the control values. 
 
Cell proliferation percentage: average OD drug exposure/average OD control X 100 
 
 
 
 
 
 
Table (6): Different concentrations used for cell viability assay. 
 
2.10- RNA Isolation, cDNA Synthesis and RT-PCR: 
 
RNA isolation was performed using TRizol Reagent (Invitrogen Life Technologies, Carlsbad, 
California, USA) according to manufacturer's instruction manual.  After decanting the culture 
media from the wells, 1ml of TRIzol reagent was added to each well. This was followed by 
Drug Concentration 
Tubacin 50, 25, 12.5, 6.25, 3.125, 1.56, 0.781uM 
Niltubacin 50, 25, 12.5, 6.25, 3.125, 1.56, 0.781uM 
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incubation for two min at room temperature. Lysed cells were then collected and transferred 
to a chilled microcentrifuge tube on ice. For each 1 mL of TRizol reagent, 0.2 mL of 
chloroform was added. Tubes were then vigorously shaked by hand for 15 seconds. This step 
was followed by an incubation time of three min on ice. Tubes were centrifuged for 15 min at 
12,000 × g/ 4°C.  Tubes were then angled at 45° to remove the aqueous phase of the sample 
by pipetting the solution while avoiding the interphase and the organic layer.  The aqueous 
phase was then placed in new tube on ice. 0.5 mL of isopropanol was added to the recovered 
supernatant and incubated on ice for 10 min the solution was then centrifuged at 12,000 × g 
for 15 min at 4°C. The supernatant was then removed leaving the RNA pellet at the bottom.  
To wash the pellet 1 mL of 75% ethanol were used per 1 mL of TRIzol reagent. Tubes were 
centrifuged at 7500 × g for 5 min at 4°C to discard the wash. The RNA pellet was left to dry 
in air for10 min .The RNA pellet was then dissolved in RNase-free water. To determine RNA 
concentration UV spectrophotometer (Beckman Coulter DU ® 700 Series) was used. 2 μl 
RNA were diluted to a total of 100 μl of distilled water and measured at λ260 and λ280, the 
following formula was used to determine the concentration. 
RNA concentration (µg/µl) = [OD260 x (dilution factor) x 40]/1000 
 
cDNA was synthesized using RevertAid First Strand cDNA Synthesis Kit (ThermoScientific, 
Rockford, Illinois, USA).  The following concentrations were used: 1µl of oligo (dT) 18 
primer, 1µg of RNA and 10 µl nuclease-free water. Samples were then briefly centrifuged 
and left incubated for 5 min at 65°C. After centrifugation, samples were placed on ice. These 
reagents were added in the following order; 4µl 5X Reaction Buffer, 2 µl 10 mM dNTP Mix, 
1 µl RiboLock RNase Inhibitor 20 u/µl and 1 µl RevertAid M-MuLV Reverse Transcriptase 
(200 u/µl) to a  total  of 20 µl of volume. The sample was incubated at 42°C for 60 min 
followed by increasing the temperature to 70°C for 5 min to stop the reaction. Ten µl of PCR 
products were loaded on 2 % agarose gel then stained with ethidium bromide. The gel was 
then visualized using Gel Documentation System. 
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2.11-Polymerase Chain Reaction: 
 
PCR was carried out using DreamTaq DNA Polymerase Master Mix (ThermoScientific, 
Rockford, Illinois, USA) using our designed primers LCA_V1_F, LCA_V1_R, LCA_V2_F, 
LCA_V2_R, LC3B_F and LC3B_R described in table 8. 
 
Reaction Component Concentration 
DreamTaq DNA Polymerase Master Mix 25 μL 
Forward primer 1 μL 
Reverse primer 
 
1 μL 
Template DNA 
 
5 μL 
Water nuclease-free 
 
18 μL 
Total volume 50 µl 
 
Table (7): PCR reaction components. 
 
 
 
 
 
  
 
 
 
 
 
 
Table (8):  PCR primers for LC3 genes expression.  
 
 
 
 
Primer Sequence 
LC3A-V1 forward 5’-CGTCCTGGACAAGACCAAGT-3’ 
LC3A-V1 reverse 5’-CTCGTCTTTCTCCTGCTCGT-3’ 
LC3A-V2 forward 5’-ACTCCTGACTGCATGGAAGC-3’ 
LC3A-V2 reverse 5’-GTCCACAGCTGCTTTTCCAC-3’ 
LC3B forward 5’-CGGAGAAGACCTTAAGCAG-3’ 
LC3B reverse 5’-TGACATGGTCAGGTACAAGGA-3’ 
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2.12-Bisulfite Sequencing: 
 
2.12.1- Extraction of Genomic DNA: 
 
DNA was extracted from CCHE-45 and SH-SY5Y cell lines using GeneJET Genomic DNA 
Purification Kit (ThermoScientific, Rockford, Illinois, USA), according to the manufacturer’s 
protocol. Cells at 80% confluence were detached from the culture plate using Trypsin (Lonza, 
Walkersville, Maryland,USA). The Cells were then transferred in to a microcentrifuge tube to 
be pelleted by centrifugation at 1300 rpm x g for 5 min. To resuspend the cells 200 μl of PBS 
buffer were used (Lonza, Walkersville, Maryland, USA). Next, to lyse the cells 200 μl of 
lysis solution and 20 μl of Proteinase K solution were added. To obtain a uniform suspension 
Cells were pelleted then vortexed. Samples were left incubated at 56°C for 10 min with 
occasional vortexing until the cells were lysed completely. 400 μl of 50% ethanol was added 
to the lysed cells. The lysates were then transferred to GeneJET Genomic DNA Purification 
columns and centrifuged at 6000 xg for 1 min. The GeneJET purification columns were then 
placed into a collection tube. 500 μl of wash buffer I was then added and centrifuged for one 
min at 8000 xg. This step was followed with wash buffer II and centrifugation for 3 min at 
(≥12000 x g) which is the maximum speed. The genomic DNA was then eluted with 50μl of 
elution buffer. The elution buffer was added to the center of the GeneJET Genomic DNA 
purification column membranes for complete to elution of the genomic DNA. Finally, an 
incubation period of 2 min for the samples at room temperature followed by centrifugation 
for 1 min at 8000 xg. Isolated genomic DNA was stored at -20°C. The total DNA 
concentration was measured using UV spectrophotometer (Beckman Coulter DU ® 700 
Series). 2 μl of genomic DNA were diluted to a total of 100 μl of distilled water and 
measured at λ260 and λ280. To determine the final concentration in µg/µl the following 
formula was then used. 
 
 
 
 
 
 
 
 
 
DNA concentration (µg/µl) = [OD260 x (dilution factor) x 50]/1000 
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2.12.2- Bisulfite Treatment of DNA: 
Two µg of DNA were used for bisulfite DNA modification using EpiTect Bisulfite DNA 
conversion kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. The total 
number of aliquots of the bisulfite mix was then dissolved in 800 μl RNase-free water. The 
aliquots were then vortexed until the bisulfite mix was completely dissolved. The bisulfite 
reactions were prepared as follows: 
 
 
 
 
 
 
 
 
 
 
 
Table (9): Bisulfite reaction master mix components. 
 
The bisulfite DNA conversion was performed using the following conditions: 
Denaturation at 95°C for 5 min, 
Incubation at 60°C for 25 min, 
Denaturation at 95°C for 5 min, 
Incubation at 60°C for 85 min, 
Denaturation at 95°C for 5 min, 
Incubation at 60°C for 175 min. 
Finally Hold at 4°C. 
 
2.12.3- Cleanup of Bisulfite Converted DNA: 
 
Directly after the bisulfite conversion, the bisulfite reactions were centrifuged briefly, and 
then transferred to a new 2 ml microcentrifuge tubes. 550 μl of the freshly prepared buffer BL 
containing 10 μg/ml carrier RNA was added to each of the samples. The solutions were 
mixed by vortexing and then centrifuged briefly. The whole mixture was then transferred into 
Reaction Component Concentration 
DNA solution 
 
2ng 
RNase-free water 
 
To a total of 140 μl  
Bisulfite Mix 
 
85 μl 
DNA Protect Buffer 
 
35 μl 
Total volume 
 
140 μl 
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the EpiTect spin columns. Spin columns were then centrifuged at maximum speed (≥12000 x 
g) for one min. This was followed by discarding the flow-through. For the washing step, 500 
μl Buffer BW was added to the spin columns and centrifuged at the maximum speed of 
(≥12000 x g) for one min and the flow-through was again discarded. For desulfonation, 500 
μl Buffer BD was added to the spin columns and left incubated for 15 min at room 
temperature at (25°C). Centrifugation of the spin columns at maximum speed to discard the 
flow-through was done at maximum speed for 1 min. To each spin column 500 μl Buffer BW 
was added to the spin columns and centrifuged at for 1 min at maximum speed. The flow-
through was then discarded. The washing step was repeated two times followed by 
centrifugation to remove any remaining liquid. Finally, 20 μl of the elution buffer (EB) were 
added to the center of each of the spin columns membrane to elute the DNA. The columns 
were then centrifuged for 1 min approximately at 15,000 xg. 
 
2.12.4: Bisulfite Sequencing Primer Design: 
 
Bisulfite-treated DNA was amplified using the designed bisulfite sequencing primers. 
Primers were designed using Methyl primer express® software v1.0 (Applied BioSystems, 
Life Technologies, Carlsbad, California, USA). 
 
 
Figure (10): Schematic presentation of bisulfite sequencing primers. 
 
Primer Sequence 
LC3A region1 Forward 5’-ATTTTTGGTAGTTTTTTTTTAGG-3’ 
LC3A region 1 Reverse 5’-ACAATCAAACACAAAATAAAACA-3’ 
LC3A region 2 Forward 5’-GTTTTATTTTGTGTTTGATTGTG-3’ 
LC3A region 2 Reverse 5’-TCACAACATTCCTTAAAAAAAA-3’ 
 
Table (10): Bisulfite sequencing primers. 
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2.12.5: Polymerase Chain Reaction: 
As previously described. 
 
2.12.6: Size Selection on Agarose: 
 Onto 1% agarose gel, 100 μl of sequencing PCR products were loaded followed by staining 
with ethidium bromide. The gel was then visualized. GeneJET Gel Extraction Kit (Thermo 
Scientific, Rockford, Illinois, USA) was used to extract the PCR product according the 
manufacturer's protocol. Using a clean scalpel, the gel containing the DNA fragment was 
excised and transferred into a 15 ml tube. The binding buffer was then added with the ratio 1 
volume: 1 weight to the gel slices. The mixtures were then incubated at 60°C for another 10 
min until the gel was completely dissolved. The dissolved gel solutions were transferred to 
the purification columns and centrifuged at max speed for 1 min.  The columns were placed 
into the same collection tubes and the flow-through was discarded. 600 µl of the wash buffer 
were added to the GeneJET purification columns and centrifuged for another 1 min to fully 
remove any residual washing buffer. For elution, the GeneJET purification columns were 
placed into a new 1.5 ml microcentrifuge tubes and fifty µl of elution buffer were added to 
the centre of the column membranes.  The tubes were then centrifuged for an additional 1 
min and the DNA was kept under -80°c. 
 
2.12.7-Tailing Reaction: 
The tailing reaction was carried out using the non-proof reading Taq DNA Polymerase 
Recombinant enzyme (ThermoScientific, Rockford, Illinois, USA) as follows: The reaction 
mixture was incubated for 2 min at 70 ºC. 
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Table (11): Tailing reaction components. 
 
2.12.8-Purification: 
 
Purification was carried out using PCR Purification Kit (ThermoScientific Rockford, Illinois, 
USA) according to manufacturer's protocol. To a ratio of 1:1 the tailing reaction was added to 
the binding buffer and transferred to the Gene JET purification columns. The columns were 
then centrifuged for 1 min .The flow-through was discarded, followed by the addition of 100 
μl of Binding Buffer to the Gene JET purification columns and centrifuged for 1 min. The 
Gene JET purification columns were then transferred into a new 2 ml microcentrifuge tube. 
To elute, 25 μl of the elution buffer were added to the purification column membranes and 
followed by a centrifugation for 1 min. 
 
2.12.9- Bisulfite PCR Cloning: 
 
PCR products were cloned using InsTAclone PCR Cloning Kit (ThermoScientific, Rockford, 
Illinois, USA). The ligation reactions mixture were set as follows; 3 μl of 5X ligation buffer, 
0.17 pmol vector pTZ57R/T, 6 μl of purified PCR, 1 μl T4 DNA Ligase giving a total volume 
of 30 μl. The Ligation mixtures were left incubated for 1 hour at room temperature (22°C). E-
Coli JM109 competent cells (TaKaRa, Mountain view, California, USA) were left to thaw on 
an ice bath directly before use. 50 μl of thawed cells were mixed gently with 2.5 μl of each 
ligation mixture for bacterial transformation and kept on the ice bath for another 30 min. 
Reaction Component Concentration 
PCR product 
 
20 μl 
Taq Buffer with KCl (10X) 
 
5 μl 
25 mM MgCl2 
 
3 μl 
Taq polymerase 
 
1.25 μl 
dATP (10mmol) 
 
1 μl 
Water 
 
19.75 μl 
Total volume 
 
50 μl 
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Cells were then instantaneously heat shocked for 45 sec at 42 ⁰C and quickly returned to the 
ice bath for another 2 min. 500 μl of pre –incubated SOC medium at 37 ⁰C were added to the 
competent cells and left incubated while shaking (160-225 rpm) for another 1 hour at 37 ⁰C. 
SOC media containing transformed E-Coli were then placed on selective media containing 20 
mg/ml X-Gal, 100 mM IPTG and 50 mg/ml ampicillin.  
 
2.12.10- Plasmid Extraction: 
 
Plasmid extraction was carried out using GeneJET Plasmid Miniprep Kit (ThermoScientific, 
Rockford, Illinois, USA) according to manufacturer's recommendation. Positive colonies 
were used to inoculate 5 ml of LB medium supplemented with the 50 mg/ml ampicillin 
antibiotic. Bacterial cultures were incubated while shaking at 200-250 rpm, overnight at 
37°C. The cultures were then pelleted by centrifugation at 8000 rpm in a microcentrifuge for 
2 min at room temperature. Harvested cells were resuspended in 250 µl of the resuspension 
solution.  Cells were then transferred to a new microcentrifuge tubes. The lysis solution was 
then added to lyse the bacterial cells. The tubes were then inverted for 4-6 times to mix 
thoroughly until the solution became viscous and slightly clear. The tubes were then 
centrifuged for an additional 5 min to pellet the debris and DNA. The upper supernatants 
phase was then transferred to the spin columns by pipetting. Spin columns were centrifuged 
for another 1 min and discarded the flow-through. For washing, 500 µl of the wash solution 
were pipetted to the GeneJET spin columns and followed by centrifugation for 60 sec. This 
wash was repeated two times. Finally, 25 μl of the elution buffer were added to the of the 
purification column membranes and centrifuged for 1 min to elute the total plasmid DNA.  
 
2.12.11- Colony PCR Identification: 
 
The DNA was amplified using universal M13/pUC Sequencing Primers (Thermo Scientific, 
Rockford, Illinois, USA) using Dream Taq polymerase (Thermo Scientific, Rockford, 
Illinois, USA) the total reaction volume was 50 µl: 
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Reaction Component Concentration 
DreamTaq DNA Polymerase Master Mix 
 
25 μL 
Forward primer 
 
1 μL 
Reverse primer 
 
1 μL 
Template DNA 
 
5 μL 
Water nuclease-free 
 
18 μL 
Total volume 
 
50 µl 
 
Table (12): Colony PCR reaction components. 
 
2.12.12- DNA Sequencing: 
 
Sequencing was done in our lab using 3130 DNA Analyzer following the BigDye® 
Terminator v1.3 Cycle Sequencing protocol (Applied BioSystems, Life Technologies, 
Carlsbad, California, USA). Sequences from ten clones from each sample were then analyzed 
using BiQ Analyzer to identify methylated and unmethylated CG dinucleotides. 
 
Reaction Component Concentration 
Terminator ready reaction mix 8ul 
Template Equivalent  to 300 ng 
Primer 3.2 pmol 
H2O Up to 20ul 
Total volume 20ul 
 
Table (13): Sequencing PCR reaction master mix components. 
 
2.13- Cloning and Expression of LC3A Gene in Choroid Plexus Cell Line: 
 
2.13.1- LC3A Amplification: 
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RNA and cDNA synthesis was done as mentioned above; LC3A-V1 and LC3A-V2 
transcripts were amplified from SH-SY5Y and cells using primers LCA_V1_cDNA_F, 
LCA_V1_cDNA_R, LCA_V2_cDNA_F and LCA_V2_cDNA_R.  
 
Primer Name Sequence 
LCA_V1_cDNA-F 5’-AAAAAGAATTCATGCCCTCAGACCGGCC-3’ 
LCA_V1_cDNA-R 5’-AAAAAGGATCCTCAGAAGCCAAGGTTTCC-3’ 
LCA_V2_cDNA-F 5’-AAAAAGAATTCATGAAGATGAGATTCTTCAGTT-3’ 
LCA_V2_cDNA_R 5’-AAAAAGGATCCTCAGAAGCCGAAGGTTTCC-3’ 
 
Table (14): LC3A-varient I and LC3A-varient II cloning primers. 
 
50 μl of PCR products were loaded onto 1% agarose gels stained with ethidium bromide. The 
gel was visualized using Gel Documentation System. DNA was extracted using GeneJET Gel 
Extraction Kit K0691 (Thermo Scientific, Rockford, Illinois, USA) according to 
manufacturer's protocol as previously described. 
 
2.13.2: Double Digestion: 
 
Purified PCR product and p-IRES2-AcGFP Plasmid (Clonetech, Mountain View, California, 
USA), were double digested with EcoR1 and BamH1 restriction enzymes (ThermoScientific, 
Rockford, Illinois, USA) as follow: 
 
 
 
 
 
 
 
 
 
Table (15): Restriction master mix. 
 
Restriction enzymes master mix Concentration 
Water, nuclease free Up to 20ul 
10X Fast Digest buffer 2ul 
Plasmid DNA(0.2ug) Variable 
FastDigest EcoR1 1ul 
FastDigest BamH1 1ul 
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The reaction was mixed gently and incubated at 37°C for 5 min. This step was followed by a 
purification step using PCR Purification Kit (ThermoScientific, Rockford, Illinois, USA) as 
described earlier. 
 
2.13.3: pIRES2-AcGFP Plasmid LC3A Insert Ligation: 
The Vector – insert reaction mixture was prepared as follow: 
Ligation Reaction Components Concentration 
Linear Vector DNA 20-100ng 
Insert  DNA 5:1 
10X T4 DNA ligase buffer 2ul 
T4 DNA ligase 1ul 
Water, nuclease free To 20ul 
 
Table (16): p-IRES2-AcGFP Plasmid LC3A insert ligation mixture. 
The reaction was incubated for 10 min at 22°C followed by transformation. 
 
2.13.4-Transformation of Cloned Plasmid: 
 DH alpha Competent Cells (TaKaRa, Mountain View, California, USA) were thawed on ice 
bath just before use. Gently cells were mixed with 5 μl of the ligation mixture for bacterial 
transformation. Cells were then kept on ice for 30 min. This step was followed by a heat 
shock at 42｡C for 45 sec, cells were then returned to ice for an additional 2 min. 500 µl of 
SOC medium pre-incubated at 37｡C were added to the cells and left incubated while shaking 
at 225 rpm for 1 hour at 37｡C. cells were then plated on kanamycin selective media. Plasmid 
preparation was then performed on selected colonies as previously described using GeneJET 
Plasmid Miniprep Kit (ThermoScientific, Rockford, Illinois, USA). Positive colonies were 
sequenced to confirm correct sequences for both variants to match LC3A-V1 (NM_032514.3) 
and LC3A-V2 (NM_181509.2). 
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2.13.5: Lipofectamine Transfection: 
CCHE-45 Cells were cultured and left to reach 90% confluency, Lipofectamine 2000 (Life 
Technologies, Carlsbad, California, USA) was then diluted in serum free media, mixed with 
2.5 ug of DNA (empty vector, LC3A-V1 or LC3A-V2 ) and incubated for 5 min at room 
temperature. The DNA-lipid complex was then added to the cells and incubated for 24, 48 or 
72 hours. 
2.14-BrainSpan Data Analysis: 
Human BrainSpan project was used to obtain RPKM for the LC3A (ENSG00000101460) and 
LC3B (ENSG00000140941). Expression values were calculated for each gene according to 
developmental stage or across different brain regions. Analysis was performed using R 
statistical language version 3.2.2. 
 
2.15-Statistical Analysis:  
All experiments were repeated three times. Data are expressed as + SEM. The significance of 
difference among means was evaluated using paired Test. Significant differences were 
defined as p ≤ 0.05. 
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3-RESULTS 
 
3-1: Constitutive formation of aggresomes in choroid plexus carcinoma line CCHE-45 is 
repressed by HDAC6 inhibitor.  
 
We propagated a primary cell line, named CCHE-45, from a CPC surgical excision sample. 
Identity with the original tumor was verified using Multiplex Cell Authentication service 
(MCA), which utilizes a single-nucleotide polymorphism (SNP) profiling approach. Cells 
were passaged over forty times before considered immortal. Karyotyping was done in the 
pathology lab in children cancer hospital 57357.CCHE-45 cells presented with two clones, 
one clone was triploid (62~75 chromosomes) and the second clone was hexaploid (137 
chromosomes). Structural abnormalities included translocation (2;18)(q32;q23), (1;3)(?;q27) 
and (20;22)(p11;q11) and del(17)(p11) (Figure 11 ) in both clones whereas the hexaploid 
clone had two copies from each translocation 
 
 
 
 
 
 
 
 
 
 
 
 
 
When immunostained with vimentin, a marker for choroid plexus tumors, CCHE-45 cells 
displayed a single perinuclear vimentin positive inclusion in all cells and in different passages 
(early and late); however, it varied in their intensity and size (Figure 12).  
 
 
Figure 11: FISH analysis using red and green probes to detect Tp53 gene and 
centromere, translocation t(1;3) and translocation t(2;18). 
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The presence of vimentin cage like structures is characteristic of aggresomes and is formed 
by the collapse of the intermediate filament. Examination of CCHE-45 cells by transmission 
electron microscopy (TEM) further confirmed the presence of dense to light 2-3 µm in 
diameter perinuclear structures in most of the examined cells (Figure 13).  
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Aggresomes subcellular localization was identified by the formation of vimentin 
capsules (white arrows) at the MTOC. CCHE-45 cells were cultured under normal condition, 
fixed and immunostained with anti-vimentin (green) and visualized using Alexa Flour 488 anti-
rabbit IgG antibody. Cells were counterstained with DAPI (blue) to visualize the nucleus. 
Figure 13: TEM examination of CCHE-45 cell line showing aggresomes ultra structures (a= 
aggresomes, n= nucleus). 
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These inclusion bodies varied in its density and in size. To ensure that the collapse of 
vimentin filaments was not a feature of the cell line and it is present in the original tumor, we 
examined a cell pellet from CCHE-45 cells and compared it to its original tumor tissue. Both 
CCHE-45 cells and the parent tumor displayed similar structures (Figures 14A and 14B). 
Unexpectedly, cytokeratin also contributed to the structure of aggresomes (Figures 14A and 
14B). 
 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
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We further examined the pattern of vimentin and cytokeratin expression in CPP and ACPP. 
Both tumors displayed a homogenous cytoplasmic pattern for both markers suggesting that 
aggresomes are unique to CPC (Figure 17C).   
 
We further examined the pattern of vimentin and cytokeratin expression in CPP and ACPP. 
Both tumors displayed a homogenous cytoplasmic pattern for both markers suggesting that 
aggresomes are unique to CPC (Figure 14C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To exclude any malfunction in the Ubiquitin proteasome System (UPS) in the CCHE45 cell 
line proteasome activity was tested. UPS failure may result in accumulation of misfolded 
proteins in the form of aggresomes. CCHE-45 was compared with two other cell lines SHSY-
5Y and SKNAS cell lines, (Figure 15) using proteosome assay loading solution (Abcam), and 
measured at EX/EM 490/620. 
Figure 14: 
A. CCHE-45 cell pellet was FFPE and immuno-stained with cytokeratin and vimentin. 
B. CCHE-45 original tumor biopsy obtained at surgical resection was FFPE and immune-
stained with cytokeratin and vimentin.  
 
Figure 14C: CPP and ACPP H&E preparation and immunohistochemical analysis for 
vimentin and cytokeratin. 
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Misfolded or aggregated proteins that cannot be eliminated by the proteosome are 
concentrated by HDAC6 and transported by the action of the dynein motor protein to the 
aggresomes. It has been previously shown that inhibitors of HDAC6 have an antitumor effect 
when coupled with conventional therapy. In this context, we evaluated the effect of different 
concentration of tubacin and its inactive analog niltubacin on CCHE-45 cells. Significant 
reduction in CCHE-45 proliferation was reported in a dose-dependent manner with no change 
in niltubacin treated cells (p-value = 0.01) (Figure 16).  
 
 
 
 
 
 
 
Figure 15: Proteasome activity assay comparing CCHE45 with SHSY5Y and SKNAS cell lines 
20S activity was measured according to protocol, relative fluorescence intensity was measured 
with a plate reader.CCHE45 showed high activity. 
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Treatment with tubacin resulted in the increase of acetylated α-tubluin and no change in 
vimentin protein levels (Figure 17), supporting the known effect of tubacin as an HDAC6 
inhibitor on α-tubulin acetylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: The effect of tubacin and niltubacin on CCHE-45 cell line was evaluated by cell 
viability assay. Cells were treated with different concentration of both drugs for 48 hours 
before treating with WST-1 for 4 hours; absorbance was then read at 440 nm. Results were 
averaged over three separate experiments. Error bars represent ± S.E.M, represent significant 
p-value where p ≤ 0.05. 
Figure 17: Immunoblot analysis for CCHE-45 after treatment with DMSO, tubacin 
(15µM), niltubacin (15µM) or non-treated (control). β-actin was used as a loading control.  
 
66 
 
Furthermore, due to the significant effect of tubacin on CCHE-45 proliferation, we 
hypothesized that tubacin treatment will result in disappearance of aggresomes as a 
consequence to HDAC6 inhibition. Despite HDAC6 inhibition, aggresomes were detected in 
tubacin treated cells however, they presented mainly as hollow cage structures (Figure 18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3-2:Effect of nutrient deprivation on autophagy markers and aggresome clearence .  
 
The presence of aggresomes has been linked to cellular proteotoxic overload that cannot be 
eliminated by the proteasome. Consequently autophagy becomes the main route for 
aggresomes clearance. To further address the contribution of autophagy to the observed 
phenotype, we treated CCHE-45 cells with HBSS for 2 and 6 hours. The induction of 
autophagy was initially monitored by the change in LC3B and LC3A processing. While 
LC3B and LC3A protein levels were reduced in the neuroblastoma line SH-SY5Y after 
nutrient deprivation for 2 and 6 hours (Figure 19), CCHE-45 cells displayed reduction in 
LC3B with no detectable LC3A protein in control cells and no change in vimentin levels 
(Figure 19).  
Figure 18: Immunofluorescence staining of CCHE-45 cells treated with 15µM of tubacin 
for 48 hours. CCHE-45 cells were immunostained with vimentin (green) and counterstained 
using DAPI. 
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Due to potential cross-reactivity between available antibodies for both LC3A and LC3B, both 
proteins immunoblots were always performed on separate membranes. The reduction in 
LC3B levels and the lack of change in vimentin protein levels following nutrient deprivation 
suggested no effect on aggresome clearance, accordingly IF was further used to monitor 
autophagy in both cell lines. IF for LC3B primarily showed nuclear localization under control 
condition and formed cytoplasmic puncta upon nutrient deprivation in CCHE-45 (Figures 
20A) confirming autophagy. Furthermore, both LC3B and the lysosomal marker LAMP2 co-
localized with each other or with vimentin upon induction of autophagy (Figure 20A).  
 
 
 
 
 
 
Figure 19: CCHE-45 and SH-SY5Y cells were cultured under normal condition or serum 
starved for 2 or 6 hours in HBSS. Whole cell lysates were collected and analyzed by 
Western blot analysis. β-actin was used as a loading control. 
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However, upon autophagy induction LC3A co-localized with LC3B either to the aggresomes 
or to other cellular sites (Figure 20A). LC3B was primarily nuclear in SH-SY5Y under 
normal conditions while LC3A protein was detected in the cytoplasm and the nucleus (Figure 
20B). When treated with HBSS for 2 hours, LC3B displayed a cytoplasmic puncta indicative 
of autophagy induction while LC3A became entirely cytoplasmic with some co-localization 
with LC3B protein. On the other hand LAMP2 co-localized with both LC3A and LC3B 
(Figure 20B).  
Figure 20A: Cells were cultured under normal condition or serum starved in HBSS for 2 
hours. CCHE-45 cells were coimmunostained with vimentin and LC3B, vimentin and 
LAMP2 or LC3B and LAMP2. Cells were fixed in 4% paraformaldehyde, immunostained 
with anti-LC3B, anti-LC3A, anti-vimentin or anti-LAMP2 and visualized using Alexa Fluor 
488 goat anti-rabbit antibody or Alexa Fluor 555 goat anti-mouse. 
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Despite the induction of autophagy, aggresomes were detected in CCHE-45 cells, however 
they formed hollow ring like structures similar to tubacin treated cells suggestive of altered 
vimentin assembly. TEM for CCHE-45 cells showed autophagic vacuoles present in close 
proximity to aggresomes 
 
 
 
 
 
 
 
 
 
3-3: Silencing of LC3A-V1 expression in choroid plexus carcinoma tumors by intergenic 
CpG island methylation.  
Figure 20B: SH-SY5Y cells were cultured under normal condition or serum starved in HBSS 
for 2 hours. Cells were fixed in 4% paraformaldehyde, immunostained with anti-LC3B, anti-
LC3A, anti- LC3A and LAMP2 or LC3B and LAMP2. Cells were visualized using Alexa Fluor 
488 goat anti-rabbit antibody or Alexa Fluor 555 goat anti-mouse. DAPI was used as 
counterstain to visualize the nucleus. 
Figure 20 C: TEM examination CCHE-45 and SH-SY5Y cells using JEOL (JEM-1400 T). 
Cells were serum starved in HBSS for 2 hours before fixation for TEM analysis. a = 
aggresomes, n = nucleus, white arrow = autophagic vacuoles 
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3-3: Silencing of LC3A-V1 expression in choroid plexus carcinoma tumors by intergenic 
CpG island methylation 
 
Recent reports have shown that LC3A expression is absent in several tumors and corresponds 
to poor prognosis. The absence of LC3A protein in CCHE-45 coupled with previous reports 
of epigenetic inactivation of LC3A-V1 in a number of tumors incited us to test for its 
silencing in CCHE-45 cells . To verify that the lack of expression of LC3A in CCHE-45 is 
not related to the tissue of origin, BrainSpan transcriptome dataset were used to examine the 
expression of LC3A and LC3B in normal brain tissues (Figure 21). 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: LC3A and LC3B gene expression as a function of different developmental 
stages (upper panel) and as a function of different regions in the brain (lower panel) using 
RNA-Seq data from the BrainSpan Project. Expression of LC3A and LC3B were detected 
in all developmental stages and at different part of the brain. pcw = post conception weeks, 
mon = month, yrs = years, Ocx = occipital neocortex, M1C-S1C = primary motor-sensory 
cortex, AMY = amygdaloid complex, MGE = medial ganglionic somatosensory 
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 LC3A and LC3B were found to be expressed in all brain regions and during different 
developmental stages. LC3A gene has been recently shown to have two transcriptional 
variants which differ in transcription start site (Figure 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Expression of both LC3A variants were absent in CCHE-45 cells, while only LC3A-V1 was 
present in SH-SY5Y cells, supporting that variant one is the predominant variant (Figure 23). 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Schematic representation of LC3A exon-intron structure showing the difference 
in transcriptional start site between LC3A-V1 and LC3AV-2 (Bai et al, 2012). 
Figure 23: Expression of LC3A –V1, V2 and LC3B were examined using RT-PCR in 
CCHE-45 and SH-SY5Y cells. β-actin was used as an internal control.  
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Furthermore, examining both LC3A and LC3B in the parent tumor tissue supports that 
inactivation of the former (Figure 24).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We further examined the CpG island status of LC3A-V1 CCHE-45 in comparison to SH-
SY5Y which is previously reported to be methylated in a wide range of tumors including 
multiple myeloma cells which are known to form aggresomes. Concordant with this data, is 
the fact that  
Loss of LC3A-V1 expression in CCHE-45 was due to intergenic CpG island methylation 
(Figure 25A). Bisulfite sequencing of CCHE-45 parent tumor indicated complete promoter 
methylation in all ten clones examined (Figure 25B).  
 
Figure 24: Immunohistochemical analysis for LC3A and LC3B expression in CCHE-45 
original tumor. LC3A was detected in normal brain tissue (region a) while tumor area (region 
b) was negative for LC3A expression. On the other hand LC3B expression was detected in 
normal and tumor tissue region (c and d) respectively.  
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Figure 25A: Bisulfite modified DNA PCR products from CCHE-45 and SH-SY5Y, the 
diagrams show methylated CG dinucleotide in CCHE-45 R1 and R2 (closed circles) with no 
methylation detected in SH-SY5Y (open circles). Primers were designed to amplify region 1 
and region 2 (R1 and R2 respectively) to examine the methylation status of CpG island 
upstream of LC3A-V1 using bisulfite sequencing.  
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Further treatment of CCHE-45 with the general demethylating agent 5-Aza-2-deoxycytidine 
(5-AZA-dC) resulted in the re-expression of LC3A (Figure 26), supporting the role of 
methylation in the regulation of LC3A-V1 expression.  
 
 
 
 
 
 
 
Figure 25B: Bisulfite sequencing for CCHE-45 original tumor. Region 2 was amplified 
using R2 primer set. Methylated CG dinucleotide is indicated by closed circles. 
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We next examined the expression of both genes in CPTs using immunohistochemical 
analysis. While LC3B expression was detected in all tumors, LC3A expression was positive 
in CPP and either focal or absent in both ACPP and CPC (Figure 27).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Schematic representation for immunostaining for 19 cases choroid plexus 
carcinoma (blue), atypical choroid plexus carcinoma (yellow) or choroid plexus papilloma 
(olive) stained with vimentin, LC3A or LC3B. Solid, partial and clear color indicates 
positive, focal and negative stain respectively. 
Figure 26: Western blot analysis for CCHE-45 cells treated with 10µm 5-AZA-dC for 4 
days then serum starved in HBSS for 2 hrs. LC3A protein was restored following 5-AZA-dC 
treatment. No change in vimentin expression was detected. 
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3.4-LC3A re-expression induces aggresome clearance by lysosomal recruitment that is 
independent of autophagosome formation. 
 
Because of the correlation between aggresomes and LC3A-V1 silencing, we reasoned that the 
lack of expression in CPC may affect aggresomes accumulation. To further elucidate the role 
of LC3A, we cloned LC3A-V1 or LC3A-V2 cDNA downstream of a CMV promoter and 
transiently transfected CCHE-45 cells with empty vector or LC3A-V1 or LC3A-V2. 
Transfection efficiency was monitored by GFP positivity. The expression of LC3A was 
further confirmed by immunoblot analysis (Figure 28). A decrease in LC3B was observed in 
LC3A-V1 transfected cells (Figure 28).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To visualize the effect of LC3A on aggresomes, CCHE-45 cells were immune-stained for 
vimentin 48 hours post transfection. Consistent with 5AZA-dC treatment, LC3A displayed a 
cytoplasmic filament like appearance (Figure 29). Furthermore, less number of aggresomes 
was observed and vimentin displayed a filament like organization or hollow circles rather 
than dense localized peri-nuclear inclusions (Figure 29). Furthermore, LC3A mainly 
surrounded the aggresomes forming a ring around the inclusion or was in close proximity 
with minimal colocalization. LAMP2 co-localized with LC3A and surrounded the 
aggresomes as well as detected within the aggresomes (Figure 29). 
Figure 28: Western blot analysis for CCHE-45 transfected with p-IRES2-AcGFP empty 
vector (EV), p-IRES2-AcGFP-LC3A-V1 (LC3A-V1) or p-IRES2-AcGFP-LC3A-V2 (LC3A-
V2). 
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Figure 29: Immunofluorescence analysis of CCHE-45 cells transfected with p-IRES2-
AcGFP empty vector) or p-IRES2-AcGFP-LC3A-V1. Cells were immunostained with LC3A 
and LC3B, vimentin and LC3A or LC3A and LAMP2 and visualized using Alexa Fluor 488 
goat anti-rabbit antibody or Alexa Fluor 555 goat anti-mouse. The figure shows the 
disappearance of aggresomes and the colocalization with LAMP2 in p-IRES2-AcGFP-
LC3A-V1 transfected cells. 
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4-DISCUSSION 
 
Mutations, metabolic challenges and stress conditions are common reasons for the production 
of aberrant proteins (Chen, Retzlaff, Roos, & Frydman, et al., 2011). Consequently, cells 
exert several quality control strategies aimed at refolding (Hartl, Bracher, & Hayer-Hartl, 
2011), degrading or sequestering aberrant protein species (Heck, Cheung, & Hampton, 2010). 
Insoluble protein deposit (IPOD) and intranuclear quality control (INQ) are two 
compartments for protein sorting and sequestration for cytoplasmic and nuclear proteins, 
respectively (Chen, Retzlaff, Roos, & Frydman, et al., 2011, Miller et al., 2005). 
Additionally, aggresomes are specialized, cytoplasmic cage-like structures that form at the 
microtubule organizing centers (MTOC) to sequester misfolded proteins (Kawaguchi, 
Kovacs, McLaurin, Vance, et al., 2003). The role of protein sequestration into inclusion 
bodies in cancer is not well defined. Here we report the development of a new choroid plexus 
carcinoma cell line CCHE-45. The cells were characterized by the presence of a single cage 
like inclusion body at juxtanuclear position that was positive for vimentin. These structures 
have been identified previously as aggresomes (Johnston et al., 1998). Recently, the JUxta 
Nuclear Quality control compartment (JUNQ) was used to describe vimentin positive 
structures that share similar cellular position as aggresomes (Kaganovich, Kopito, & 
Frydman, 2008).Furthermore, it was proposed that aggresomes may represent a mature state 
of JUNQ (Heck, Cheung, & Hampton, 2010). In the case of CCHE-45 cells, their constitutive 
presence in all cells and lack of mobility supports aggresome description rather than JUNQ. 
While most reports suggest that aggresomes are formed by single intermediate filaments 
(Johnston et al., 1998, Saliba, Munro, Luthert, & Cheetham, 2002), we find that both 
cytokeratin and vimentin contribute to the cage like structure of aggresomes in CPC. The 
absence of aggresomes in both CPP and ACCP and their presence in CPC supports the notion 
that their accumulation is more likely to be associated with aggressive tumors. The formation 
of aggresomes was shown to be dependent on the collection of aggregates by HDAC6 and 
dynin motor proteins (Kawaguchi, Kovacs, McLaurin, Vance, et al., 2003). The significant 
decrease in cell proliferation following treatment with tubacin highlights the role of 
aggresomes as a protective mechanism against aberrant proteins. Furthermore, the 
disassembly of aggresomes following HDAC6 inhibition with no change in vimentin protein 
levels suggests that aggresome assembly is coupled to aggregates transport (Kawaguchi, 
Kovacs, McLaurin, Vance, et al., 2003). 
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While aggresomes are considered a cytoprotective mechanism, they are ultimately eliminated 
by autophagy. Monitoring autophagy has proven to be challenging due to difference in tissue 
response to stress as well as limitations associated with different assays (Klionsky,  2016). 
LC3B is commonly used as a marker for induction of autophagy (Tanida, Ueno, & 
Kominami, et al., 2005); however MAP1LC3/LC3 family members encompass LC3A, LC3B 
and LC3C where the former two have been reported to participate in autophagosome 
formation (Shpilka, Weidberg, Pietrokovski, & Elazar, 2011, Koukourakis, Kalamida, 
Giatromanolaki, Zois, et al., 2015). Examining both LC3A and LC3B following nutrient 
deprivation, we find that both proteins are present and processed to form cytoplasmic puncta 
indicative of autophagy activation in SH-SY5Y cells. In contrast, LC3B presented with both 
bands (LC3B-I and LC3B-II) under normal growth condition and no detectable LC3A protein 
in CCHE-45 cells. The increased signal for autophagosome detected by the presence of 
lipdiated form of LC3B and the cytoplasmic puncta for LC3B supports the activation of 
autophagy at a basal level in CCHE-45 cells. At the same time, the decrease in LC3B-I and 
LC3B-II protein levels following nutrient deprivation supports the notion of enhanced 
autophagy flux in CCHE-45 cells.  Based on these results we propose that CCHE-45 cells 
exhibit enhanced autophagy flux to overcome proteotoxic stress. Furthermore, the 
disassembly of the vimentin cage following autophagy induction supports the role of induced 
autophagy as a regulator of aggresomes. By inducing non-selective macroautophagy aberrant 
proteins are removed which in turn results in altered assembly of the vimentin cage rather 
than removal of aggresomes by engulfment. This notion is further supported by TEM for 
CCHE-45 cells showing autophagic vacuoles present in close proximity to aggresomes.  This 
is in line with previous reports for autophagic vacuoles and lysosome recruitment to 
aggresomes to facilitate its degradation following proteasome inhibition (Zaarur, Meriin, 
Bejarano, Xu, et al., 2014).  
Deregulation of signalling pathways and microtubule associated proteins which have been 
shown to correlate with the clinical outcomes in some tumors. For instance LC3B-II down 
regulation correlated with poor survival in GBM (Huang, Bai, Chen, Li, & Lu, 2010) and the 
loss of LC3A expression by promoter-silencing was found in different tumor cell lines (Bai, 
Inoue, Kawano, & Inazawa, 2012). Furthermore, both LC3A and LC3B were found to form 
stone like structures which correlated with poor prognosis (El-Mashed, O’Donovan, Kay, 
Abdallah, Cathcart, & O’Sullivan, et al.,2015). Analysis of BrainSpan RNA-Seq data 
identifies LC3A and LC3B to be ubiquitously expressed in the brain during different 
developmental stages. While LC3B is expressed in CCHE-45 cells, LC3A-V1 was silenced by 
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promoter methylation in CCHE-45 and primary CPC supporting previous reports of LC3A-V1 
inactivation. Interestingly, multiple myeloma, which is known to form aggresomes, shows 
inactivation of LC3A-V1 by the same mechanism. These results support a potential 
correlation between LC3A-V1 gene silencing and the development of aggresomes. The 
disassembly of the vimentin cage following LC3A-V1 expression coupled with recruitment 
of LAMP2 independent of LC3B suggestive of autophagy activation independent of 
macroautophagy. These results support the hypothesis that under the stress imposed by 
protein overload, LC3A modulates cellular basal quality control.  
In conclusion, protein misfolding and aggregation has been mainly investigated in 
neurological disorders. In cancer, understanding cellular response to aberrant protein which is 
a common feature to cancer cells has been primarily investigated using ectopic expression of 
aberrant proteins coupled with proteasome inhibitors. CCHE-45 cells provide a new model 
for understanding aggresome dynamics without disruption of tumor environment. Moreover, 
it serves as a new model to investigate how cancer cells employ autophagy quality-control to 
achieve proteostasis highlighting a new role for LC3A protein. Finally our work identifies 
aggresomes as a potential new molecular target for CPC and other tumors with a similar 
phenotype. 
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5-FUTURE DIRECTION 
 
In our research we were mainly investigating the vimentin cage forming the aggresomal 
structure; our next step is to study the expression of the intermediate filament cytokeratin. 
Cytokeratin was found to contribute to the structure of aggresomes formation in our cell line 
and the original tumor. As with the vimentin expression we will study the effect of HDAC6 
inhibitor on cell proliferation. Autophagy activation by nutrient deprivation and how would it 
affect the cytokeratin structure and concentration would be further studied.  We will also 
study the effect of treatment with a demethylating agent such as 5-Aza-dC and transfection 
with LC3A gene on the structure of the cytokeratin and compare it with the effect on the 
vimentin cage. In addition, we need to further study the different component contributing in 
the aggresome structure other than vimentin and cytokeratin. 
 In this thesis study we were mainly concerned about the mechanisms contributing to 
clearance of the aggresomes such as the ubiquitin proteasomal pathway and autophagy. Our 
next aim is to tackle the mechanisms that lead to its formation in the first place. The different 
stresses that lead to protein misfolding and the reason they ended up contained by 
aggresomes from their ubiquitination status to solubility will be further investigated.  
A recent study showed an asymmetric segregation of aggresomes during mitosis, we plan to 
study the fate of aggresomes during cell division in CCHE-45, using different molecular 
biology techniques and many cytological assays.  We will investigate whether the cell line 
will undergo normal mitosis. The segregation pattern of the aggresomes whether symmetric 
or asymmetric will be compared with other cell lines. 
At last we would like to target the aggresomes with different potent and selective new 
generation inhibitors such as Tubastatin A, we will verify its effect on cell proliferation, 
vimentin and cytokeratin expression and aggresomal clearance. Ultimately, we hope to able 
to find a potential target in choroid plexus carcinoma that can be used for future treatment. 
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and conditions applying to this transaction. You also agree to the Billing 
and Payment terms and conditions established by Copyright Clearance 
Center (CCC) at the time you opened your Rightslink account. 
LIMITED LICENSE 
The AACR grants exclusively to you, the User, for onetime, non-
exclusive use of this material for the purpose stated in your request and 
used only with a maximum distribution equal to the number you 
identified in the permission process. Any form of republication must be 
completed within one year although copies made before then may be 
distributed thereafter and any electronic posting is limited to a period of 
one year. Reproduction of this material is confined to the purpose and/or 
media for which permission is granted. Altering or modifying this 
material is not permitted. However, figures and illustrations may be 
minimally altered or modified to serve the new work. 
GEOGRAPHIC SCOPE 
Licenses may be exercised as noted in the permission process 
RESERVATION OF RIGHTS 
The AACR reserves all rights not specifically granted in the combination 
of 1) the license details provided by you and accepted in the course of 
this licensing transaction, 2) these terms and conditions , and 3) CCC's 
Billing and Payment terms and conditions. 
DISCLAIMER 
You may obtain permission via Rightslink to use material owned by 
AACR. When you are requesting permission to reuse a portion for an 
AACR publication, it is your responsibility to examine each portion of 
content as published to determine whether a credit to, or copyright notice 
of a third party owner is published next to the item. You must obtain 
permission from the third party to use any material which has been 
reprinted with permission from the said third party. If you have not 
obtained permission from the third party, AACR disclaims any 
responsibility for the use you make of items owned by them. 
LICENSE CONTINGENT ON PAYMENT  
While you may exercise the rights licensed immediately upon issuance 
of the license at the end of the licensing process for the transaction, 
provided that you have disclosed complete and accurate details of your 
proposed use, no license is finally effective unless and until full payment 
is received from you, either by the publisher or by the CCC, as provided 
in CCC's Billing and Payment terms and conditions. If full payment is 
not received on a timely basis, then any license preliminarily granted 
shall be deemed automatically revoked and shall be void as if never 
granted. Further, in the event that you breach any of these terms and 
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conditions, or any of the CCC's Billing and Payment terms and 
conditions, the license is automatically revoked and shall be void as if 
never granted. Use of materials as described in a revoked license, as well 
as any use of the materials beyond the scope of an unrevoked license, 
may constitute copyright infringement and the publisher reserves the 
right to take any and all action to protect its copyright in the materials. 
COPYRIGHT NOTICE 
You must include the following credit line in connection with your 
reproduction of the licensed material: "Reprinted (or adapted) from 
Publication Title, Copyright Year, Volume/Issue, Page Range, Author, 
Title of Article, with permission from AACR". 
TRANSLATION 
This permission is granted for non-exclusive world English rights only. 
WARRANTIES 
Publisher makes no representations or warranties with respect to the 
licensed material. 
INDEMNIFICATION 
You hereby indemnify and agree to hold harmless the publisher and 
CCC, and their respective officers, directors, employees and agents, 
from and against any and all claims arising out of your use of the 
licensed material other than as specifically authorized pursuant to this 
license. 
REVOCATION 
The AACR reserves the right to revoke a license for any reason, 
including but not limited to advertising and promotional uses of AACR 
content, third party usage and incorrect figure source attribution. 
NO TRANSFER OF LICENSE 
This license is personal to you and may not be sublicensed, assigned, or 
transferred by you to any other person without publisher's written 
permission. 
NO AMENDMENT EXCEPT IN WRITING 
This license may not be amended except in a writing signed by both 
parties (or, in the case of publisher, by CCC on publisher's behalf). 
OBJECTION TO CONTRARY TERMS 
Publishers hereby objects to any terms contained in any purchase order, 
acknowledgement, check endorsement or other writing prepared by you, 
which terms are inconsistent with these terms and conditions or CCC's 
Billing and Payment terms and conditions. These terms and conditions 
together with CCC's Billing and Payment terms and conditions (which 
are incorporated herein) comprise the entire agreement between you and 
publisher (and CCC) concerning this licensing transaction. In the event 
of any conflict between your obligations established by these terms and 
conditions, and those established by CCC's Billing and Payment terms 
and conditions, these terms and conditions shall control. 
THESIS/DISSERTATION TERMS  
If your request is to reuse an article authored by you and published by 
the AACR in your dissertation/thesis, your thesis may be submitted to 
your institution in either in print or electronic form. Should your thesis 
be published commercially, please reapply. 
ELECTRONIC RESERVE 
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If this license is made in connection with a course, and the Licensed 
Material or any portion thereof is to be posted to a website, the website 
is to be password protected and made available only to the students 
registered for the relevant course. The permission is granted for the 
duration of the course. All content posted to the website must maintain 
the copyright information notice. 
JURISDICTION 
This license transaction shall be governed by and construed in 
accordance with the laws of Pennsylvania. You hereby agree to submit 
to the jurisdiction of the federal and state courts located in Pennsylvania 
for purposes of resolving any disputes that may arise in connection with 
this licensing transaction. 
Other Terms and Conditions: 
v1.0 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) 
or +1-978-646-2777.  
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This Agreement between Marwa Nassar ("You") and BioScientifica 
Ltd. ("BioScientifica Ltd.") consists of your license details and the 
terms and conditions provided by BioScientifica Ltd. and Copyright 
Clearance Center. 
License Number 4077200853006 
License date  
Licensed Content Publisher BioScientifica Ltd. 
Licensed Content Publication Journal of Molecular Endocrinology 
Licensed Content Title Linking the ubiquitin–proteasome pathway to chromatin 
remodeling/modification by nuclear receptors 
Licensed Content Author H K Kinyamu, J Chen, T K Archer et al. 
Licensed Content Date Apr 1, 2005 
Licensed Content Volume 34 
Licensed Content Issue 2 
Type of Use Thesis/Dissertation 
Requestor type Publisher, not-for-profit 
Format Print, Electronic 
Portion image/photo 
Number of images/photos 
requested 
1 
Rights for Main product 
Duration of use Life of current edition 
Creation of copies for the 
disabled 
no 
With minor editing privileges yes 
For distribution to Worldwide 
In the following language(s) Original language of publication 
With incidental promotional use no 
The lifetime unit quantity of new 
product 
0 to 499 
The requesting 
person/organization is: 
American university in Cairo 
Order reference number  
Title of your thesis / dissertation Characterization of aggresomes formation in choroid 
plexus carcinoma 
Expected completion date Apr 2017 
Expected size (number of pages) 100 
Requestor Location Marwa Nassar 
3A Saad Zalam street,Maadi 
 
 
Cairo, 342 
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Egypt 
Attn: Marwa Nassar 
Publisher Tax ID GB 869 9945 28 
Billing Type Invoice 
  
Billing Address Marwa Nassar 
3A Saad Zalam street,Maadi 
 
 
Cairo, Egypt 342 
Attn: Marwa Nassar 
  
Total 0.00 GBP 
  
Terms and Conditions 
  
Introduction 
The publisher for this copyrighted material is Bioscientifica Ltd. By 
clicking "accept" in connection with completing this licensing 
transaction, you agree that the following terms and conditions apply to 
this transaction (along with the Billing and Payment terms and 
conditions established by Copyright Clearance Center, Inc. ("CCC"), at 
the time that you opened your CCC account and that are available at 
any time at ). 
Limited License 
The publisher hereby grants to you a non-exclusive license to use this 
material. Licenses are for one-time use only with a maximum 
distribution equal to the number that you identified in the licensing 
process. 
Geographic Rights: Scope 
Licenses may be exercised anywhere in the world. 
Reservation of Rights 
The publisher reserves all rights not specifically granted in the 
combination of (i) the license details provided by you and accepted in 
the course of this licensing transaction, (ii) these terms and conditions 
and (iii) CCC's Billing and Payment terms and conditions. 
Limited Contingent on Payment 
While you may exercise the rights licensed immediately upon issuance 
of the license at the end of the licensing process for the transaction, 
provided that you have disclosed complete and accurate details of your 
proposed use, no license is finally effective unless and until full 
payment is received from you (either by publisher or by CCC) as 
provided in CCC's Billing and Payment terms and conditions. If full 
payment is not received on a timely basis, then any license 
preliminarily granted shall be deemed automatically revoked and shall 
be void as if never granted. Further, in the event that you breach any of 
these terms and conditions or any of CCC's Billing and Payment terms 
and conditions, the license is automatically revoked and shall be void as 
if never granted. Use of materials as described in a revoked license, as 
well as any use of the materials beyond the scope of an unrevoked 
license, may constitute copyright infringement and publisher reserves 
the right to take any and all action to protect its copyright in the 
materials. 
Copyright NoticeYou must include the following copyright and 
permission notice in connection with any reproduction of the licensed 
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material: "Copyright [Original year of publication] [Copyright holder]." 
Warranties: None 
The publisher makes no representations or warranties with respect to 
the licensed material and adopts on its own behalf the limitations and 
disclaimers established by CCC on its behalf in its Billing and Payment 
terms and conditions for this licensing transaction. 
Indemnity 
You hereby indemnify and agree to hold harmless the publisher and 
CCC, and their respective officers, directors, employees and agents, 
from and against any and all claims arising out of your use of the 
licensed material other than as specifically authorized pursuant to this 
license. In no event shall the publisher or CCC be liable for any special, 
incidental, indirect or consequential damages of any kind arising out of 
or in connection with the use of the articles or other material derived 
from the journals, whether or not advised of the possibility of damage, 
and on any theory of liability. 
No Transfer of License 
This license is personal to you and may not be sublicensed, assigned, or 
transferred by you to any other person without the publisher's written 
permission. 
No Amendment Except in Writing 
This license may not be amended except in a writing signed by both 
parties (or, in the case of the publisher, by CCC on publisher's behalf). 
Objection to Contrary Terms 
The publisher hereby objects to any terms contained in any purchase 
order, acknowledgment, check endorsement or other writing prepared 
by you, which terms are inconsistent with these terms and conditions or 
CCC's Billing and Payment terms and conditions. These terms and 
conditions, together with CCC's Billing and Payment terms and 
conditions (which are incorporated herein), comprise the entire 
agreement between you and publisher (and CCC) concerning this 
licensing transaction. In the event of any conflict between your 
obligations established by these terms and conditions and those 
established by CCC's Billing and Payment terms and conditions, these 
terms and conditions shall control. 
STM Permissions Guidelines 
The publisher is a signatory to the STM Guidelines and as such grants 
permission to other signatory STM publishers to re-use material strictly 
in accordance with the current STM Guidelines (http://www.stm-
assoc.org/permissions-guidelines/). 
Other Terms and Conditions: 
V.1 10.26/12 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the 
US) or +1-978-646-2777.   
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Cancer Research ("American Association for Cancer Research") consists of 
your license details and the terms and conditions provided by American 
Association for Cancer Research and Copyright Clearance Center. 
License Number 4077600049559 
License date  
Licensed Content Publisher American Association for Cancer Research 
Licensed Content Publication Molecular Cancer Therapeutics 
Licensed Content Title Picking the Point of Inhibition: A Comparative Review 
of PI3K/AKT/mTOR Pathway Inhibitors 
Licensed Content Author Rodrigo Dienstmann,Jordi Rodon,Violeta Serra,Josep 
Tabernero 
Licensed Content Date 2014-05-01 
Licensed Content Volume 13 
Licensed Content Issue 5 
Type of Use Thesis/Dissertation 
Requestor type non-commercial (non-profit) 
Format print and electronic 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
Will you be translating? No 
Circulation 500 
Territory of distribution Worldwide 
Title of your thesis / dissertation Characterization of aggresomes formation in choroid 
plexus carcinoma 
Expected completion date Apr 2017 
Estimated size (number of pages) 100 
Requestor Location Marwa Nassar 
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Cairo, 342 
Egypt 
Attn: Marwa Nassar 
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Terms and Conditions 
 
American Association for Cancer Research (AACR) Terms and Conditions 
INTRODUCTION 
The Publisher for this copyright material is the American Association for 
Cancer Research (AACR). By clicking "accept" in connection with 
completing this licensing transaction, you agree to the following terms 
and conditions applying to this transaction. You also agree to the Billing 
and Payment terms and conditions established by Copyright Clearance 
Center (CCC) at the time you opened your Rightslink account. 
LIMITED LICENSE 
The AACR grants exclusively to you, the User, for onetime, non-
exclusive use of this material for the purpose stated in your request and 
used only with a maximum distribution equal to the number you 
identified in the permission process. Any form of republication must be 
completed within one year although copies made before then may be 
distributed thereafter and any electronic posting is limited to a period of 
one year. Reproduction of this material is confined to the purpose and/or 
media for which permission is granted. Altering or modifying this 
material is not permitted. However, figures and illustrations may be 
minimally altered or modified to serve the new work. 
GEOGRAPHIC SCOPE 
Licenses may be exercised as noted in the permission process 
RESERVATION OF RIGHTS 
The AACR reserves all rights not specifically granted in the combination 
of 1) the license details provided by you and accepted in the course of 
this licensing transaction, 2) these terms and conditions , and 3) CCC's 
Billing and Payment terms and conditions. 
DISCLAIMER 
You may obtain permission via Rightslink to use material owned by 
AACR. When you are requesting permission to reuse a portion for an 
AACR publication, it is your responsibility to examine each portion of 
content as published to determine whether a credit to, or copyright notice 
of a third party owner is published next to the item. You must obtain 
permission from the third party to use any material which has been 
reprinted with permission from the said third party. If you have not 
obtained permission from the third party, AACR disclaims any 
responsibility for the use you make of items owned by them. 
LICENSE CONTINGENT ON PAYMENT  
While you may exercise the rights licensed immediately upon issuance 
of the license at the end of the licensing process for the transaction, 
provided that you have disclosed complete and accurate details of your 
proposed use, no license is finally effective unless and until full payment 
is received from you, either by the publisher or by the CCC, as provided 
in CCC's Billing and Payment terms and conditions. If full payment is 
not received on a timely basis, then any license preliminarily granted 
shall be deemed automatically revoked and shall be void as if never 
granted. Further, in the event that you breach any of these terms and 
conditions, or any of the CCC's Billing and Payment terms and 
conditions, the license is automatically revoked and shall be void as if 
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never granted. Use of materials as described in a revoked license, as well 
as any use of the materials beyond the scope of an unrevoked license, 
may constitute copyright infringement and the publisher reserves the 
right to take any and all action to protect its copyright in the materials. 
COPYRIGHT NOTICE 
You must include the following credit line in connection with your 
reproduction of the licensed material: "Reprinted (or adapted) from 
Publication Title, Copyright Year, Volume/Issue, Page Range, Author, 
Title of Article, with permission from AACR". 
TRANSLATION 
This permission is granted for non-exclusive world English rights only. 
WARRANTIES 
Publisher makes no representations or warranties with respect to the 
licensed material. 
INDEMNIFICATION 
You hereby indemnify and agree to hold harmless the publisher and 
CCC, and their respective officers, directors, employees and agents, 
from and against any and all claims arising out of your use of the 
licensed material other than as specifically authorized pursuant to this 
license. 
REVOCATION 
The AACR reserves the right to revoke a license for any reason, 
including but not limited to advertising and promotional uses of AACR 
content, third party usage and incorrect figure source attribution. 
NO TRANSFER OF LICENSE 
This license is personal to you and may not be sublicensed, assigned, or 
transferred by you to any other person without publisher's written 
permission. 
NO AMENDMENT EXCEPT IN WRITING 
This license may not be amended except in a writing signed by both 
parties (or, in the case of publisher, by CCC on publisher's behalf). 
OBJECTION TO CONTRARY TERMS 
Publishers hereby objects to any terms contained in any purchase order, 
acknowledgement, check endorsement or other writing prepared by you, 
which terms are inconsistent with these terms and conditions or CCC's 
Billing and Payment terms and conditions. These terms and conditions 
together with CCC's Billing and Payment terms and conditions (which 
are incorporated herein) comprise the entire agreement between you and 
publisher (and CCC) concerning this licensing transaction. In the event 
of any conflict between your obligations established by these terms and 
conditions, and those established by CCC's Billing and Payment terms 
and conditions, these terms and conditions shall control. 
THESIS/DISSERTATION TERMS  
If your request is to reuse an article authored by you and published by 
the AACR in your dissertation/thesis, your thesis may be submitted to 
your institution in either in print or electronic form. Should your thesis 
be published commercially, please reapply. 
ELECTRONIC RESERVE 
If this license is made in connection with a course, and the Licensed 
Material or any portion thereof is to be posted to a website, the website 
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is to be password protected and made available only to the students 
registered for the relevant course. The permission is granted for the 
duration of the course. All content posted to the website must maintain 
the copyright information notice. 
JURISDICTION 
This license transaction shall be governed by and construed in 
accordance with the laws of Pennsylvania. You hereby agree to submit 
to the jurisdiction of the federal and state courts located in Pennsylvania 
for purposes of resolving any disputes that may arise in connection with 
this licensing transaction. 
Other Terms and Conditions: 
v1.0 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) 
or +1-978-646-2777.  
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